Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acne Vulgaris
Study of visfatin expression in acne patients in tissue and serum.
Acquired Immunodeficiency Syndrome
HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.
Acromegaly
A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly.
Acromegaly
Adipocytes as a Source of Increased Circulating Levels of Nicotinamide Phosphoribosyltransferase/Visfatin in Active Acromegaly.
Acromegaly
Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations.
Acromegaly
Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly.
Acute Coronary Syndrome
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Acute Coronary Syndrome
Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes.
Acute Coronary Syndrome
Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages.
Acute Coronary Syndrome
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Acute Coronary Syndrome
Nicotinamide Phosphate Transferase (NAMPT) Increases in Plasma in Patients with Acute Coronary Syndromes, and Promotes Macrophages to M2 Polarization.
Acute Coronary Syndrome
The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle.
Acute Kidney Injury
Extracellular signal-regulated kinase 1/2 regulates NAD metabolism during acute kidney injury through microRNA-34a-mediated NAMPT expression.
Acute Lung Injury
Association of PBEF gene polymorphisms with acute lung injury, sepsis, and pneumonia in a northeastern Chinese population.
Acute Lung Injury
Augmentation of Pulmonary Epithelial Cell IL-8 Expression and Permeability by Pre-B-cell Colony Enhancing Factor.
Acute Lung Injury
Critical role of PBEF expression in pulmonary cell inflammation and permeability.
Acute Lung Injury
Emodin alleviates severe acute pancreatitis-associated acute lung injury by decreasing pre-B-cell colony-enhancing factor expression and promoting polymorphonuclear neutrophil apoptosis.
Acute Lung Injury
Endothelial eNAMPT Amplifies Preclinical Acute Lung Injury: Efficacy of an eNAMPT-Neutralising mAb.
Acute Lung Injury
Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury.
Acute Lung Injury
Essential Role of Visfatin in Lipopolysaccharide and Colon Ascendens Stent Peritonitis-Induced Acute Lung Injury.
Acute Lung Injury
FK866 attenuates sepsis-induced acute lung injury through c-jun-N-terminal kinase (JNK)-dependent autophagy.
Acute Lung Injury
FK866, a Visfatin Inhibitor, Protects Against Acute Lung Injury After Intestinal Ischemia-Reperfusion in Mice via NF-?B Pathway.
Acute Lung Injury
Inhibition of Pre-B Cell Colony Enhancing Factor Reduces Lung Injury in Rats Receiving Cardiopulmonary Bypass.
Acute Lung Injury
Interactions between PBEF and oxidative stress proteins--a potential new mechanism underlying PBEF in the pathogenesis of acute lung injury.
Acute Lung Injury
MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866.
Acute Lung Injury
Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration.
Acute Lung Injury
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders.
Acute Lung Injury
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in LPS-induced neutrophil extracellular traps.
Acute Lung Injury
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Acute Lung Injury
Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis.
Acute Lung Injury
Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury.
Acute Lung Injury
Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome.
Acute Lung Injury
Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.
Acute Lung Injury
Regulation of inflammatory cytokine expression in pulmonary epithelial cells by Pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism.
Acute Lung Injury
Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in rats.
Acute Lung Injury
Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown.
Acute Lung Injury
Visfatin Exerts Immunotherapeutic Effects in Lipopolysaccharide-Induced Acute Lung Injury in Murine Model.
Acute Lung Injury
Visfatin Plays a Significant Role in Alleviating Lipopolysaccharide-Induced Apoptosis and Autophagy Through PI3K/AKT Signaling Pathway During Acute Lung Injury in Mice.
Acute Lung Injury
Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions.
Acute Lung Injury
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Adenocarcinoma
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Adenocarcinoma
Impact of genetic variants of ABCB1, APOB, CAV1, and NAMPT on susceptibility to pancreatic ductal adenocarcinoma in Chinese patients.
Adenocarcinoma
Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level.
Adenocarcinoma
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by ?-lapachone.
Adenocarcinoma
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Adenocarcinoma
Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
Adenocarcinoma
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.
Adenocarcinoma
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
Adenocarcinoma of Lung
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Adenoma
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Adenoma
Cystathione ?-Synthase Is Increased in Thyroid Malignancies.
Adenoma
Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level.
Adenoma
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
Adenoma
The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.
Adenoma
Visfatin level in patients with colorectal adenoma.
Adenoma
Visfatin levels in hormonally inactive adrenal adenoma and their association with
metabolic parameters
Adenoma, Pleomorphic
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
Adrenal Insufficiency
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Aggressive Periodontitis
Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: An immunohistochemical analysis.
Albuminuria
Adipokines as a link between obesity and chronic kidney disease.
Albuminuria
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Albuminuria
Role of Nampt-Sirt6 Axis in Renal Proximal Tubules in Extracellular Matrix Deposition in Diabetic Nephropathy.
Alopecia
Assessment of Metabolic Profile and Ischemia-modified Albumin Level in Patients with Alopecia Areata: A Case-Control Study.
Alzheimer Disease
A microdeletion in Alzheimer's disease disrupts NAMPT gene.
Alzheimer Disease
Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease.
Alzheimer Disease
Alzheimer's disease, ceramide, visfatin and NAD.
Amyotrophic Lateral Sclerosis
Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death.
Anemia
Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Anemia
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Aneurysm
Relationsh?p of spontaneous subarachnoid haemorrhage and cerebral aneurysm to serum Visfatin and Nesfatin-1 levels.
Angina Pectoris
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Angina, Stable
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Angina, Stable
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Angina, Unstable
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Anhedonia
Fasting- and ghrelin-induced food intake is regulated by NAMPT in the hypothalamus.
Anovulation
Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome.
Aortic Aneurysm, Thoracic
Nicotinamide Phosphoribosyltransferase in Smooth Muscle Cells Maintains Genome Integrity, Resists Aortic Medial Degeneration and Is Suppressed in Human Thoracic Aortic Aneurysm Disease.
Aortic Valve Stenosis
Reduced visfatin levels in aortic stenosis increase after aortic valve replacement and may contribute to reverse left ventricular remodelling.
Appendicitis
Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis?
Appendicitis
Serum visfatin levels in acute appendicitis.
Arrhythmias, Cardiac
Usefulness of Visfatin as a Predictor of Atrial Fibrillation Recurrence After Ablation Procedure.
Arterial Occlusive Diseases
The role of Visfatin in atherosclerotic peripheral arterial obstructive disease.
Arteritis
Endothelial NLRP3 Inflammasome Activation and Enhanced Neointima Formation in Mice by Adipokine Visfatin.
Arthralgia
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee.
Arthritis
Alterations in adipocyte glucose transporter GLUT4 and circulating adiponectin and visfatin in rat adjuvant induced arthritis.
Arthritis
Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis.
Arthritis
Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate.
Arthritis
Epigenetic regulation of NfatC1 transcription and osteoclastogenesis by nicotinamide phosphoribosyl transferase in the pathogenesis of arthritis.
Arthritis
Nicotinamide mononucleotide-elicited NAMPT signaling activation aggravated adjuvant-induced arthritis in rats by affecting peripheral immune cells differentiation.
Arthritis
Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.
Arthritis
Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP.
Arthritis
Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.
Arthritis
Osteoarthritis and obesity: experimental models.
Arthritis
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Arthritis
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Arthritis
Serum Vaspin Levels Are Associated with the Development of Clinically Manifest Arthritis in Autoantibody-Positive Individuals.
Arthritis
The association between clinically suspect arthralgia and adipokines in obese patients.
Arthritis
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Arthritis
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Arthritis
[Serum and synovial adiponectin, resistin, and visfatin levels in rheumatoid arthritis patients : Relation to disease activity.]
Arthritis, Experimental
Alterations in adipocyte glucose transporter GLUT4 and circulating adiponectin and visfatin in rat adjuvant induced arthritis.
Arthritis, Experimental
Metabolomics Analysis Reveals Therapeutic Effects of ?-Mangostin on Collagen-Induced Arthritis in Rats by Down-regulating Nicotinamide Phosphoribosyltransferase.
Arthritis, Experimental
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Arthritis, Experimental
Selective inhibition of PBEF/Visfatin/NAMPT suppresses leukocyte infiltration and cartilage degradation.
Arthritis, Experimental
Visfatin and Rheumatoid Arthritis: Pathogenetic Implications and Clinical Utility.
Arthritis, Juvenile
Decreased expression of nicotinamide phosphoribosyltransferase in patients with juvenile idiopathic arthritis receiving methotrexate.
Arthritis, Juvenile
Nicotinamide Phosphoribosyltransferase Attenuates Methotrexate Response in Juvenile Idiopathic Arthritis and In Vitro.
Arthritis, Juvenile
Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP.
Arthritis, Psoriatic
Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis.
Arthritis, Psoriatic
Obesity in autoimmune diseases: not a passive bystander.
Arthritis, Psoriatic
Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity.
Arthritis, Rheumatoid
Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases.
Arthritis, Rheumatoid
Adipokines in rheumatoid arthritis.
Arthritis, Rheumatoid
Associations between Adipokines in Arthritic Disease and Implications for Obesity.
Arthritis, Rheumatoid
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta-analysis.
Arthritis, Rheumatoid
Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort.
Arthritis, Rheumatoid
Epigenetic regulation of NfatC1 transcription and osteoclastogenesis by nicotinamide phosphoribosyl transferase in the pathogenesis of arthritis.
Arthritis, Rheumatoid
Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Arthritis, Rheumatoid
Nesfatin-1 and visfatin expression is associated with reduced atherosclerotic disease risk in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.
Arthritis, Rheumatoid
Obesity in autoimmune diseases: not a passive bystander.
Arthritis, Rheumatoid
PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?
Arthritis, Rheumatoid
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Arthritis, Rheumatoid
Plasma levels of leptin and visfatin in rheumatoid arthritis patients; is there any relationship with joint damage?
Arthritis, Rheumatoid
Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis.
Arthritis, Rheumatoid
Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.
Arthritis, Rheumatoid
Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
Arthritis, Rheumatoid
Serum chemerin and visfatin levels and their ratio as possible diagnostic parameters of rheumatoid arthritis.
Arthritis, Rheumatoid
The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy.
Arthritis, Rheumatoid
Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Visfatin and adiponectin as novel markers for evaluation of metabolic disturbance in recently diagnosed rheumatoid arthritis patients.
Arthritis, Rheumatoid
Visfatin and Rheumatoid Arthritis: Pathogenetic Implications and Clinical Utility.
Arthritis, Rheumatoid
Visfatin as a therapeutic target for rheumatoid arthritis.
Arthritis, Rheumatoid
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Arthritis, Rheumatoid
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Arthritis, Rheumatoid
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Arthritis, Rheumatoid
Visfatin: a potential therapeutic target for rheumatoid arthritis.
Arthritis, Rheumatoid
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Arthritis, Rheumatoid
[Serum and synovial adiponectin, resistin, and visfatin levels in rheumatoid arthritis patients : Relation to disease activity.]
Asthma
Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis.
Asthma
Serum visfatin levels are decreased in schoolchildren with atopic asthma.
Asthma
Visfatin and ghrelin: can they be forthcoming biomarkers or new drug targets for asthma?
Astrocytoma
Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma ME45 cells.
Astrocytoma
Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study.
Atherosclerosis
Adipo/cytokines in atherosclerotic secretomes: increased visfatin levels in unstable carotid plaque.
Atherosclerosis
Adipocytokines: The pied pipers.
Atherosclerosis
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis.
Atherosclerosis
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure.
Atherosclerosis
Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.
Atherosclerosis
Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Atherosclerosis
Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis.
Atherosclerosis
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Atherosclerosis
Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.
Atherosclerosis
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Atherosclerosis
Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes.
Atherosclerosis
Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice by upregulating visfatin expression.
Atherosclerosis
Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study.
Atherosclerosis
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Atherosclerosis
Dingxin recipe alleviates atherosclerosis injury in ApoE-knockout mice via downregulation of visfatin expression and inhibition of the visfatin-induced inflammatory response.
Atherosclerosis
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
Atherosclerosis
Elevated serum visfatin levels in patients with acute myocardial infarction.
Atherosclerosis
Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke.
Atherosclerosis
Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
Atherosclerosis
Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages.
Atherosclerosis
Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease.
Atherosclerosis
Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis?
Atherosclerosis
Leukocyte Overexpression of Intracellular NAMPT Attenuates Atherosclerosis by Regulating PPAR?-Dependent Monocyte Differentiation and Function.
Atherosclerosis
NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat-induced insulin resistance.
Atherosclerosis
Nicotinamide Phosphate Transferase (NAMPT) Increases in Plasma in Patients with Acute Coronary Syndromes, and Promotes Macrophages to M2 Polarization.
Atherosclerosis
Nicotinamide phosphoribosyltransferase aggravates inflammation and promotes atherosclerosis in ApoE knockout mice.
Atherosclerosis
Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages.
Atherosclerosis
Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.
Atherosclerosis
Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
Atherosclerosis
Polydatin Attenuates Atherosclerosis in ApoE
-
?
-
Mice through PBEF Mediated Reduction of Cholesterol Deposition.
Atherosclerosis
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.
Atherosclerosis
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Atherosclerosis
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Atherosclerosis
Serum Amyloid a Promotes Visfatin Expression in Macrophages.
Atherosclerosis
Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study.
Atherosclerosis
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Atherosclerosis
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Atherosclerosis
Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction.
Atherosclerosis
The association between plasma visfatin levels and ED.
Atherosclerosis
The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome.
Atherosclerosis
The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis
Atherosclerosis
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Atherosclerosis
The role of Visfatin in atherosclerotic peripheral arterial obstructive disease.
Atherosclerosis
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
Atherosclerosis
Visfatin (nicotinomide phosphoribosyltransferase/pre-B cell colony-enhancing factor) activates eNOS via Akt and MAP kinases and improves endothelial function.
Atherosclerosis
Visfatin and Cardio-Cerebro-Vascular Disease.
Atherosclerosis
Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction.
Atherosclerosis
Visfatin contributes to the differentiation of monocytes into macrophages through the differential regulation of inflammatory cytokines in THP-1 cells.
Atherosclerosis
Visfatin Destabilizes Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice.
Atherosclerosis
Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36.
Atherosclerosis
Visfatin Is a Positive Regulator of MCP-1 in Human Adipocytes In Vitro and in Mice In Vivo.
Atherosclerosis
Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease.
Atherosclerosis
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Atherosclerosis
Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly.
Atherosclerosis
VISFATIN PROMOTES FOAM CELL FORMATION BY DYSREGULATING CD36, SRA, ABCA1, AND ABCG1 EXPRESSION IN RAW264.7 MACROPHAGES.
Atherosclerosis
Visfatin, glucose metabolism and vascular disease: a review of evidence.
Atherosclerosis
Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases.
Atherosclerosis
[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Atherosclerosis
[Novel adipokines: links between obesity and atherosclerosis].
Atherosclerosis
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Atherosclerosis
[Resistin: a pathogenic factor or a biomarker of metabolic disorders and inflammation?]
Atherosclerosis
[Study on visfatin-induced inflammation and necroptosis via LOX-1 in human umbilical vein endothelial cells].
Atherosclerosis
[The research advances in the relationship between visfatin and cancer].
Atrial Fibrillation
Nicotinamide Phosphoribosyltransferase (Nampt)/Nicotinamide Adenine Dinucleotide (NAD) Axis Suppresses Atrial Fibrillation by Modulating the Calcium Handling Pathway.
Atrial Fibrillation
Usefulness of Visfatin as a Predictor of Atrial Fibrillation Recurrence After Ablation Procedure.
Atrial Fibrillation
Visfatin as a predictor of obstructive sleep apnea in atrial fibrillation patients.
Autoimmune Diseases
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
Autoimmune Diseases
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Autoimmune Diseases
Visfatin induces MUC8 and MUC5B expression via p38 MAPK/ROS/NF-?B in human airway epithelial cells.
Axial Spondyloarthritis
Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.
Basal Ganglia Hemorrhage
Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.
Basal Ganglia Hemorrhage
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
Behcet Syndrome
Visfatin Levels in Behcet's Disease.
beta-Thalassemia
Relationship between Serum Visfatin and Vascular Inflammation Markers Level in Beta Thalassemia Major Patients.
Bone Diseases
Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.
Brain Diseases
Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.
Brain Injuries
Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.
Brain Injuries
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
Brain Injuries
NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Brain Injuries
NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation.
Brain Injuries
Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury.
Brain Injuries
Neuroprotective effects of FK866 against traumatic brain injury: Involvement of p38/ERK pathway.
Brain Injuries, Traumatic
Change in plasma visfatin level after severe traumatic brain injury.
Brain Injuries, Traumatic
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
Brain Injuries, Traumatic
NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Brain Injuries, Traumatic
Plasma visfatin, associated with a genetic polymorphism -1535C>T, is correlated with C-reactive protein in Chinese Han patients with traumatic brain injury.
Brain Injuries, Traumatic
Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis.
Brain Injuries, Traumatic
Visfatin expression and genetic polymorphism in patients with traumatic brain injury.
Brain Ischemia
Cerebral ischemia is exacerbated by extracellular nicotinamide phosphoribosyltransferase via a non-enzymatic mechanism.
Brain Ischemia
Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury.
Brain Ischemia
Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia.
Brain Ischemia
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
Brain Ischemia
NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation.
Brain Ischemia
Nampt/PBEF/Visfatin Exerts Neuroprotective Effects Against Ischemia/Reperfusion Injury via Modulation of Bax/Bcl-2 Ratio and Prevention of Caspase-3 Activation.
Brain Ischemia
Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury.
Brain Ischemia
Protein Kinase C Epsilon Promotes Cerebral Ischemic Tolerance Via Modulation of Mitochondrial Sirt5.
Brain Ischemia
Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade.
Brain Ischemia
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Brain Ischemia
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Breast Neoplasms
Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
Breast Neoplasms
Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Breast Neoplasms
Circulating leptin, soluble leptin receptor, free leptin index, visfatin and selected leptin and leptin receptor gene polymorphisms in sporadic breast cancer.
Breast Neoplasms
Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
Breast Neoplasms
Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
Breast Neoplasms
Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.
Breast Neoplasms
Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion.
Breast Neoplasms
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Breast Neoplasms
Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells.
Breast Neoplasms
Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer.
Breast Neoplasms
Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters.
Breast Neoplasms
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Breast Neoplasms
Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer.
Breast Neoplasms
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Breast Neoplasms
Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.
Breast Neoplasms
Extracellular NAMPT/visfatin causes p53 deacetylation via NAD production and SIRT1 activation in breast cancer cells.
Breast Neoplasms
Extracellular NAMPT/Visfatin induces proliferation through ERK1/2 and AKT and inhibits apoptosis in breast cancer cells.
Breast Neoplasms
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Breast Neoplasms
FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.
Breast Neoplasms
High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival.
Breast Neoplasms
Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1.
Breast Neoplasms
In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children.
Breast Neoplasms
Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Breast Neoplasms
Inhibition of Nicotinamide Phosphoribosyltransferase Induces Apoptosis in Estrogen Receptor-Positive MCF-7 Breast Cancer Cells.
Breast Neoplasms
Investigating the effect of visfatin on ERalpha phosphorylation (Ser118 and Ser167) and ERE-dependent transcriptional activity.
Breast Neoplasms
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Breast Neoplasms
MicroRNA-494 induces breast cancer cell apoptosis and reduces cell viability by inhibition of nicotinamide phosphoribosyltransferase expression and activity.
Breast Neoplasms
MiR-613 Promotes Cell Death in Breast Cancer Cells by Downregulation of Nicotinamide Phosphoribosyltransferase and Reduction of NAD.
Breast Neoplasms
NAMPT regulates PKM2 nuclear location through 14-3-3?: Conferring resistance to tamoxifen in breast cancer.
Breast Neoplasms
NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
Breast Neoplasms
Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Breast Neoplasms
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
Breast Neoplasms
Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women.
Breast Neoplasms
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Breast Neoplasms
Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.
Breast Neoplasms
Significance of Some Non-Invasive Biomarkers in the Early Diagnosis and Staging of Egyptian Breast Cancer Patients.
Breast Neoplasms
Suppression of nicotinamide phosphoribosyltransferase expression by miR-154 reduces the viability of breast cancer cells and increases their susceptibility to doxorubicin.
Breast Neoplasms
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Breast Neoplasms
The association between obesity related adipokines and risk of breast cancer: a meta-analysis.
Breast Neoplasms
The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.
Breast Neoplasms
The NAD(+) salvage pathway modulates cancer cell viability via p73.
Breast Neoplasms
Up-regulation of miR-381 inhibits NAD+ salvage pathway and promotes apoptosis in breast cancer cells.
Breast Neoplasms
Visfatin Enhances Breast Cancer Progression through CXCL1 Induction in Tumor-Associated Macrophages.
Breast Neoplasms
Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway.
Breast Neoplasms
Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer.
Breast Neoplasms
Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer.
Breast Neoplasms
Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
Breast Neoplasms
Visfatin, breastfeeding, and breast cancer.
Carcinogenesis
A Negative Feedback Loop Between NAMPT and TGF-? Signaling Pathway in Colorectal Cancer Cells.
Carcinogenesis
A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis.
Carcinogenesis
Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma.
Carcinogenesis
Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.
Carcinogenesis
Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin.
Carcinogenesis
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Carcinogenesis
Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.
Carcinogenesis
FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.
Carcinogenesis
Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma.
Carcinogenesis
Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.
Carcinogenesis
High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.
Carcinogenesis
Intracellular NAD(H) levels control motility and invasion of glioma cells.
Carcinogenesis
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.
Carcinogenesis
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.
Carcinogenesis
Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors.
Carcinogenesis
Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
Carcinogenesis
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Carcinogenesis
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Carcinogenesis
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Carcinogenesis
Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Carcinogenesis
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Carcinogenesis
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
Carcinogenesis
Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
Carcinogenesis
Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/?-catenin signaling via increasing Axin level.
Carcinogenesis
The Role of Adipokines in Breast Cancer: Current Evidence and Perspectives.
Carcinogenesis
Visfatin levels in hormonally inactive adrenal adenoma and their association with
metabolic parameters
Carcinogenesis
[Nicotinamide phosphoribosyltransferase and its roles in cancer].
Carcinoma
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Carcinoma
Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma.
Carcinoma
Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment.
Carcinoma
Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
Carcinoma
Cystathione ?-Synthase Is Increased in Thyroid Malignancies.
Carcinoma
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Carcinoma
Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients.
Carcinoma
Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin.
Carcinoma
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Carcinoma
Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma.
Carcinoma
High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.
Carcinoma
Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Carcinoma
Increased Nicotinamide Phosphoribosyltransferase and Cystathionine-?-Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma.
Carcinoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Carcinoma
Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Carcinoma
Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.
Carcinoma
Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.
Carcinoma
miR-181a-2* expression is different amongst carcinomas from the colorectal serrated route.
Carcinoma
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Carcinoma
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Carcinoma
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Carcinoma
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
Carcinoma
[The expression of nicotinamide phosphoribosyl transferase and vascular endothelial growth factor-A in gastric carcinoma and their clinical significance].
Carcinoma, Acinar Cell
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
Carcinoma, Basal Cell
Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin.
Carcinoma, Ductal
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Carcinoma, Hepatocellular
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Carcinoma, Hepatocellular
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Carcinoma, Hepatocellular
Hormonal regulation of visfatin gene in avian Leghorn male hepatoma (LMH) cells.
Carcinoma, Hepatocellular
Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Carcinoma, Hepatocellular
Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Carcinoma, Hepatocellular
Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-?B activity and affects Nampt-dependent cell viability in Huh-7 cells.
Carcinoma, Hepatocellular
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Carcinoma, Hepatocellular
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
Carcinoma, Non-Small-Cell Lung
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Carcinoma, Non-Small-Cell Lung
Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.
Carcinoma, Non-Small-Cell Lung
NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Carcinoma, Non-Small-Cell Lung
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Carcinoma, Non-Small-Cell Lung
The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Carcinoma, Renal Cell
Association of leptin, visfatin, apelin, resistin and adiponectin with clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Cardiomegaly
Involvement of TRPC1 in Nampt-induced cardiomyocyte hypertrophy through the activation of ER stress.
Cardiomegaly
Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.
Cardiomyopathies
FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes.
Cardiomyopathies
Nicotinamide Phosphoribosyltransferase/Pre-B-Cell Colony Enhancing Factor/Visfatin Plasma Levels and Clinical Outcome in Patients With Dilated Cardiomyopathy.
Cardiomyopathy, Dilated
Association of Nicotinamide Phosphoribosyltransferase (NAMPT) Gene Polymorphisms and of Serum NAMPT Levels with Dilated Cardiomyopathy in a Chinese Population.
Cardiomyopathy, Dilated
[Expression and Initial Mechanism of Nicotinamide Phosphoribosyltransferase (NAMPT) in Dilated Cardiomyopathy].
Cardiotoxicity
Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
Cardiotoxicity
Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Cardiovascular Diseases
A novel adipocytokine visfatin protects against H(2)O(2) -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease.
Cardiovascular Diseases
Adipocytokines and metabolic syndrome.
Cardiovascular Diseases
Adipokines as possible new predictors of cardiovascular diseases: a case control study.
Cardiovascular Diseases
An elevated plasma level of visfatin increases the risk of myocardial infarction.
Cardiovascular Diseases
Angiotensin II Type-1 Receptor-JAK/STAT Pathway Mediates the Induction of Visfatin in Angiotensin II-Induced Cardiomyocyte Hypertrophy.
Cardiovascular Diseases
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Cardiovascular Diseases
Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.
Cardiovascular Diseases
Effect of simvastatin treatment on plasma visfatin levels in obese women.
Cardiovascular Diseases
FK866 compromises mitochondrial metabolism and adaptive stress responses in cultured cardiomyocytes.
Cardiovascular Diseases
HIF-1? mediates visfatin-induced CTGF expression in vascular endothelial cells.
Cardiovascular Diseases
Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome.
Cardiovascular Diseases
Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.
Cardiovascular Diseases
Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin.
Cardiovascular Diseases
NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.
Cardiovascular Diseases
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Cardiovascular Diseases
Serum visfatin levels in women with polycystic ovary syndrome.
Cardiovascular Diseases
The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle.
Cardiovascular Diseases
The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
Cardiovascular Diseases
The metabolic syndrome and adipocytokines.
Cardiovascular Diseases
The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus.
Cardiovascular Diseases
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
Cardiovascular Diseases
Visfatin -948G/T and resistin -420C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases.
Cardiovascular Diseases
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Cardiovascular Diseases
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Cardiovascular Diseases
Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.
Cardiovascular Diseases
VISFATIN PROMOTES FOAM CELL FORMATION BY DYSREGULATING CD36, SRA, ABCA1, AND ABCG1 EXPRESSION IN RAW264.7 MACROPHAGES.
Cardiovascular Diseases
Visfatin Promotes Monocyte Adhesion by Upregulating ICAM-1 and VCAM-1 Expression in Endothelial Cells via Activation of p38-PI3K-Akt Signaling and Subsequent ROS Production and IKK/NF-?B Activation.
Cardiovascular Diseases
Visfatin, glucose metabolism and vascular disease: a review of evidence.
Cardiovascular Diseases
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
Cardiovascular Diseases
Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases.
Cardiovascular Diseases
White adipose tissue and cardiovascular disease.
Cardiovascular Diseases
[Inflammatory biomarkers: the link between obesity and associated pathologies]
Cardiovascular Diseases
[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].
Carotid Artery Diseases
Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.
Carotid Artery Diseases
Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis.
Carotid Artery Diseases
Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study.
Carotid Artery Diseases
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Carotid Artery Diseases
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Carotid Artery Diseases
Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.
Carotid Artery Diseases
Leukocyte Overexpression of Intracellular NAMPT Attenuates Atherosclerosis by Regulating PPAR?-Dependent Monocyte Differentiation and Function.
Carotid Artery Diseases
Nesfatin-1 and visfatin expression is associated with reduced atherosclerotic disease risk in patients with rheumatoid arthritis.
Carotid Artery Diseases
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
Carotid Artery Diseases
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Carotid Stenosis
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
Carotid Stenosis
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Cerebral Hemorrhage
Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage.
Cerebral Hemorrhage
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
Cerebral Hemorrhage
Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage.
Cerebral Infarction
Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease.
Cerebrovascular Disorders
Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease.
Cerebrovascular Disorders
NAMPT and NAMPT-controlled NAD Metabolism in Vascular Repair.
Cerebrovascular Disorders
The emerging role of leptin, Adiponectin and Visfatin in Ischemic/Hemorrhagic stroke.
Cervical Intraepithelial Neoplasia
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Cholecystitis
Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis.
Cholecystitis, Acute
Elevated plasma visfatin levels correlate with conversion of laparoscopic cholecystectomy to open surgery in acute cholecystitis.
Cholecystitis, Acute
Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis.
Cholelithiasis
Visfatin and gallstone disease.
Cholelithiasis
Visfatin-a proinflammatory adipokine-in gallstone disease.
Cholelithiasis
[The role of the behaviour food hormones in the development of gallstone disease].
Cholera
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Chondrosarcoma
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
Chondrosarcoma
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Chondrosarcoma
Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway.
Chronic Periodontitis
Comparative Evaluation of Salivary Visfatin Levels in Healthy and Periodontally Diseased Patients before and after Scaling and Root Planing.
Chronic Periodontitis
Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease.
Chronic Periodontitis
Effect of Non-surgical Periodontal Therapy on Serum and Salivary Concentrations of Visfatin in Patients with Chronic Periodontitis.
Chronic Periodontitis
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Chronic Periodontitis
Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-?, and Interleukin-6 in Gingival Crevicular Fluid in Patients with Type 2 Diabetes and Chronic Periodontitis.
Chronic Periodontitis
Evaluation of association between Porphyromonas gingivalis and visfatin levels in chronic periodontitis patients.
Chronic Periodontitis
Expression of Leptin and Visfatin in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Using Enzyme-Linked Immunosorbent Assay and Real-Time Polymerase Chain Reaction.
Chronic Periodontitis
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
Chronic Periodontitis
Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome.
Chronic Periodontitis
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Chronic Periodontitis
Periodontitis contributes to aberrant metabolism in type 2 diabetes mellitus rats by stimulating the expression of adipokines.
Chronic Periodontitis
Salivary Visfatin Concentration in Chronic Periodontitis Patients.
Chronic Periodontitis
Salivary visfatin concentrations in patients with chronic periodontitis: An analysis before and after periodontal therapy.
Chronic Periodontitis
The comparison of visfatin levels of gingival crevicular fluid in systemic lupus erythematosus and chronic periodontitis patients with healthy subjects.
Chronic Periodontitis
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Chronic Periodontitis
Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: An immunohistochemical analysis.
Chronic Periodontitis
Visfatin levels in gingival crevicular fluid and serum before and after non-surgical treatment for periodontal diseases.
Colitis
Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.
Colitis
NAD metabolism fuels human and mouse intestinal inflammation.
Colitis
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
Colitis
The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat.
Colitis, Ulcerative
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Colitis, Ulcerative
Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
Colitis, Ulcerative
Serum Visfatin Levels in Ulcerative Colitis.
Colitis, Ulcerative
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Colitis-Associated Neoplasms
NAD metabolism fuels human and mouse intestinal inflammation.
Colonic Neoplasms
Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment.
Colonic Neoplasms
Visfatin and global histone H3K9me levels in colon cancer.
Colonic Neoplasms
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Colorectal Neoplasms
A Negative Feedback Loop Between NAMPT and TGF-? Signaling Pathway in Colorectal Cancer Cells.
Colorectal Neoplasms
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Colorectal Neoplasms
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Colorectal Neoplasms
Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Colorectal Neoplasms
Association of plasma visfatin with risk of colorectal cancer: An observational study of Chinese patients.
Colorectal Neoplasms
Changes in subcellular localization of visfatin in human colorectal HCT-116 carcinoma cell line after cytochalasin B treatment.
Colorectal Neoplasms
Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients.
Colorectal Neoplasms
Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Colorectal Neoplasms
High-throughput proteomics integrated with gene microarray for discovery of colorectal cancer potential biomarkers.
Colorectal Neoplasms
Increased nicotinamide adenine dinucleotide pool promotes colon cancer progression by suppressing reactive oxygen species level.
Colorectal Neoplasms
miR-181a-2* expression is different amongst carcinomas from the colorectal serrated route.
Colorectal Neoplasms
NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
Colorectal Neoplasms
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Colorectal Neoplasms
Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells.
Colorectal Neoplasms
Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
Colorectal Neoplasms
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
Colorectal Neoplasms
Resistin and Visfatin Expression in HCT-116 Colorectal Cancer Cell Line.
Colorectal Neoplasms
Role of visfatin in promoting proliferation and invasion of colorectal cancer cells by downregulating SDF-1/CXCR4-mediated miR-140-3p expression.
Colorectal Neoplasms
Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
Colorectal Neoplasms
Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/?-catenin signaling via increasing Axin level.
Colorectal Neoplasms
The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.
Colorectal Neoplasms
Visfatin induces stromal cell-derived factor-1 expression by ?1 integrin signaling in colorectal cancer cells.
Colorectal Neoplasms
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Colorectal Neoplasms
Visfatin level in patients with colorectal adenoma.
Colorectal Neoplasms
Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
Coma
Change in plasma visfatin level after severe traumatic brain injury.
Communicable Diseases
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Communicable Diseases
Regulation of NAMPT in Human Gingival Fibroblasts and Biopsies.
Communicable Diseases
Serum adipokine profiles in Kawasaki disease.
Connective Tissue Diseases
Adipokines in connective tissue diseases.
Corneal Edema
NAD+ precursors protect corneal endothelial cells from UVB-induced apoptosis.
Coronary Artery Disease
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Coronary Artery Disease
Adipokine gene expression in adipocytes isolated from different fat depots of coronary artery disease patients.
Coronary Artery Disease
Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis.
Coronary Artery Disease
Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.
Coronary Artery Disease
Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.
Coronary Artery Disease
Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population.
Coronary Artery Disease
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Coronary Artery Disease
Increased expression of NAMPT in PBMC from patients with acute coronary syndrome and in inflammatory M1 macrophages.
Coronary Artery Disease
Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.
Coronary Artery Disease
Increased Peripheral Blood Visfatin Concentrations May Be a Risk Marker of Coronary Artery Disease: A Meta-Analysis of Observational Studies.
Coronary Artery Disease
Mechanistic insights into the link between visfatin gene C-1535T polymorphism and coronary artery disease: an in vitro study.
Coronary Artery Disease
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Coronary Artery Disease
Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis.
Coronary Artery Disease
Serum Levels of Visfatin and Interleukin-6 in Non-Obese Versus Obese Men with Coronary Artery Disease.
Coronary Artery Disease
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Coronary Artery Disease
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Coronary Artery Disease
The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle.
Coronary Artery Disease
The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome.
Coronary Artery Disease
The mRNA Expression and Circulating Levels of Visfatin and Their Correlation with Coronary Artery Disease Severity and 25-Hydroxyvitamin D.
Coronary Artery Disease
Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients.
Coronary Artery Disease
[Detection of visfatin level of plasma in patients with coronary artery diseases]
Coronary Disease
Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Coronary Disease
Levels and clinical significance of serum homocysteine (Hcy), high-density lipoprotein cholesterol (HDL-C), vaspin, and visfatin in elderly patients with different types of coronary heart disease.
Coronary Disease
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Coronary Disease
Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure.
Coronary Stenosis
Levels and clinical significance of serum homocysteine (Hcy), high-density lipoprotein cholesterol (HDL-C), vaspin, and visfatin in elderly patients with different types of coronary heart disease.
Crohn Disease
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Crohn Disease
Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
Crohn Disease
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Cysts
Biomarkers of Endothelial Dysfunction in Women With Polycystic Ovary Syndrome.
Cysts
Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice.
Demyelinating Diseases
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Dengue
Genetic Profiling and Comorbidities of Zika Infection.
Dermatitis, Atopic
Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis.
Dermatitis, Atopic
Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.
Dermatomyositis
Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measures.
Diabetes Complications
Role of adipocytokines in predicting the development of diabetes and its late complications.
Diabetes Mellitus
Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.
Diabetes Mellitus
Adipocytokines and metabolic syndrome.
Diabetes Mellitus
An evaluation of visfatin levels in obese subjects.
Diabetes Mellitus
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Diabetes Mellitus
Assessment of Salivary Adipokines Resistin, Visfatin, and Ghrelin as Type 2 Diabetes Mellitus Biomarkers.
Diabetes Mellitus
Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Diabetes Mellitus
Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes.
Diabetes Mellitus
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Diabetes Mellitus
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Diabetes Mellitus
Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle.
Diabetes Mellitus
Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Diabetes Mellitus
Consumption of extra-virgin olive oil rich in phenolic compounds improves metabolic control in patients with type 2 diabetes mellitus: a possible involvement of reduced levels of circulating visfatin.
Diabetes Mellitus
Depletion of NAD pool contributes to impairment of endothelial progenitor cell mobilization in diabetes.
Diabetes Mellitus
Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration.
Diabetes Mellitus
Differential Expression of Human N-Alpha-Acetyltransferase 40 (hNAA40), Nicotinamide Phosphoribosyltransferase (NAMPT) and Sirtuin-1 (SIRT-1) Pathway in Obesity and T2DM: Modulation by Metformin and Macronutrient Intake.
Diabetes Mellitus
Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
Diabetes Mellitus
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Diabetes Mellitus
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Diabetes Mellitus
Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes.
Diabetes Mellitus
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Diabetes Mellitus
Expression of Leptin and Visfatin in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Using Enzyme-Linked Immunosorbent Assay and Real-Time Polymerase Chain Reaction.
Diabetes Mellitus
Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans.
Diabetes Mellitus
Increased insulin sensitivity in individuals with neurofibromatosis type 1.
Diabetes Mellitus
Increased levels and adipose tissue expression of visfatin in morbidly obese women. The relationship with pro-inflammatory cytokines.
Diabetes Mellitus
Insulin-like effects of visfatin on human osteoblasts.
Diabetes Mellitus
Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
Diabetes Mellitus
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Diabetes Mellitus
Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.
Diabetes Mellitus
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Diabetes Mellitus
Maternal visfatin concentration in normal pregnancy.
Diabetes Mellitus
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Diabetes Mellitus
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Diabetes Mellitus
Nampt and its potential role in inflammation and type 2 diabetes.
Diabetes Mellitus
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Diabetes Mellitus
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Diabetes Mellitus
Plasma visfatin concentrations in subjects with type 1 diabetes mellitus.
Diabetes Mellitus
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus.
Diabetes Mellitus
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Diabetes Mellitus
Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus.
Diabetes Mellitus
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Diabetes Mellitus
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Diabetes Mellitus
Rapid and sensitive detection of Nampt (PBEF/visfatin) in human serum using an ssDNA aptamer-based capacitive biosensor.
Diabetes Mellitus
Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.
Diabetes Mellitus
Relation of visfatin to cardiovascular risk factors and adipocytokines in patients with impaired fasting glucose.
Diabetes Mellitus
Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.
Diabetes Mellitus
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Diabetes Mellitus
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Diabetes Mellitus
Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus.
Diabetes Mellitus
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Diabetes Mellitus
Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus.
Diabetes Mellitus
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Diabetes Mellitus
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Diabetes Mellitus
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Diabetes Mellitus
Serum visfatin level is associated with complexity of coronary artery disease in patients with stable angina pectoris.
Diabetes Mellitus
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Diabetes Mellitus
The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion.
Diabetes Mellitus
The comparison of serum vaspin and visfatin concentrations in obese and normal weight women.
Diabetes Mellitus
The correlation between insulin-like growth factor 1 (IGF-1) and novel adipocytokines in postmenopausal women: A population-based study.
Diabetes Mellitus
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
Diabetes Mellitus
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
Diabetes Mellitus
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Diabetes Mellitus
The metabolic syndrome and adipocytokines.
Diabetes Mellitus
The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Diabetes Mellitus
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
Diabetes Mellitus
TNF-alpha alters visfatin and adiponectin levels in human fat.
Diabetes Mellitus
Visfatin concentrations in patients with endometrial cancer.
Diabetes Mellitus
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Diabetes Mellitus
Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
Diabetes Mellitus
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Diabetes Mellitus
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Diabetes Mellitus
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NF?B and JNK in human abdominal subcutaneous adipocytes.
Diabetes Mellitus
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Diabetes Mellitus
Visfatin Stimulates a Cellular Renin-Angiotensin System in Cultured Rat Mesangial Cells.
Diabetes Mellitus
Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.
Diabetes Mellitus
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
Diabetes Mellitus
Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions.
Diabetes Mellitus
White adipose tissue and cardiovascular disease.
Diabetes Mellitus
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
Diabetes Mellitus
[Visfatin level after laparoscopic Roux-en-Y gastric bypass surgery in patients with Type 2 diabetes].
Diabetes Mellitus, Type 1
Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration.
Diabetes Mellitus, Type 1
Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.
Diabetes Mellitus, Type 1
Low placental visfatin expression is related to impaired glycaemic control and fetal macrosmia in pregnancies complicated by type 1 diabetes.
Diabetes Mellitus, Type 1
Omentin-1 and NAMPT serum concentrations are higher and CK-18 levels are lower in children and adolescents with type 1 diabetes when compared to healthy age, sex and BMI matched controls.
Diabetes Mellitus, Type 1
Plasma visfatin concentrations in subjects with type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Diabetes Mellitus, Type 1
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Diabetes Mellitus, Type 2
A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity.
Diabetes Mellitus, Type 2
A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes.
Diabetes Mellitus, Type 2
Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.
Diabetes Mellitus, Type 2
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Diabetes Mellitus, Type 2
Assessment of Salivary Adipokines Resistin, Visfatin, and Ghrelin as Type 2 Diabetes Mellitus Biomarkers.
Diabetes Mellitus, Type 2
Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes.
Diabetes Mellitus, Type 2
Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Diabetes Mellitus, Type 2
Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome.
Diabetes Mellitus, Type 2
Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Diabetes Mellitus, Type 2
Consumption of extra-virgin olive oil rich in phenolic compounds improves metabolic control in patients with type 2 diabetes mellitus: a possible involvement of reduced levels of circulating visfatin.
Diabetes Mellitus, Type 2
Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.
Diabetes Mellitus, Type 2
Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes.
Diabetes Mellitus, Type 2
Depletion of NAD pool contributes to impairment of endothelial progenitor cell mobilization in diabetes.
Diabetes Mellitus, Type 2
Determinants of visfatin in type 2 diabetes patients with diabetic kidney disease: Relationship to inflammation, adiposity and undercarboxylated osteocalcin.
Diabetes Mellitus, Type 2
Differential Expression of Human N-Alpha-Acetyltransferase 40 (hNAA40), Nicotinamide Phosphoribosyltransferase (NAMPT) and Sirtuin-1 (SIRT-1) Pathway in Obesity and T2DM: Modulation by Metformin and Macronutrient Intake.
Diabetes Mellitus, Type 2
Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism.
Diabetes Mellitus, Type 2
Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
Diabetes Mellitus, Type 2
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Diabetes Mellitus, Type 2
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes.
Diabetes Mellitus, Type 2
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-?, and Interleukin-6 in Gingival Crevicular Fluid in Patients with Type 2 Diabetes and Chronic Periodontitis.
Diabetes Mellitus, Type 2
Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Expression of Leptin and Visfatin in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Using Enzyme-Linked Immunosorbent Assay and Real-Time Polymerase Chain Reaction.
Diabetes Mellitus, Type 2
Extracellular Visfatin Activates Gluconeogenesis in HepG2 Cells Through the Classical PKA/CREB-Dependent Pathway.
Diabetes Mellitus, Type 2
Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population.
Diabetes Mellitus, Type 2
Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment.
Diabetes Mellitus, Type 2
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Diabetes Mellitus, Type 2
Increased insulin sensitivity in individuals with neurofibromatosis type 1.
Diabetes Mellitus, Type 2
Insulin-like effects of visfatin on human osteoblasts.
Diabetes Mellitus, Type 2
Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Diabetes Mellitus, Type 2
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Diabetes Mellitus, Type 2
Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment.
Diabetes Mellitus, Type 2
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Nampt and its potential role in inflammation and type 2 diabetes.
Diabetes Mellitus, Type 2
Nampt: linking NAD biology, metabolism and cancer.
Diabetes Mellitus, Type 2
Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation.
Diabetes Mellitus, Type 2
Perinatal circulating visfatin levels in intrauterine growth restriction.
Diabetes Mellitus, Type 2
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Diabetes Mellitus, Type 2
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Diabetes Mellitus, Type 2
Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass.
Diabetes Mellitus, Type 2
Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Diabetes Mellitus, Type 2
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Rapid and sensitive detection of Nampt (PBEF/visfatin) in human serum using an ssDNA aptamer-based capacitive biosensor.
Diabetes Mellitus, Type 2
Reciprocal changes of serum adispin and visfatin levels in patients with type 2 diabetes after an overnight fast.
Diabetes Mellitus, Type 2
Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
Diabetes Mellitus, Type 2
Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.
Diabetes Mellitus, Type 2
Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Diabetes Mellitus, Type 2
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Diabetes Mellitus, Type 2
Resveratrol attenuates visfatin and vaspin genes expression in adipose tissue of rats with type 2 diabetes.
Diabetes Mellitus, Type 2
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Saponins as adipokines modulator: A possible therapeutic intervention for type 2 diabetes.
Diabetes Mellitus, Type 2
Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Diabetes Mellitus, Type 2
Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Diabetes Mellitus, Type 2
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Diabetes Mellitus, Type 2
Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Diabetes Mellitus, Type 2
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Diabetes Mellitus, Type 2
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Diabetes Mellitus, Type 2
Structure-functional changes in eNAMPT at high concentrations mediate mouse and human beta cell dysfunction in type 2 diabetes.
Diabetes Mellitus, Type 2
The -1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects.
Diabetes Mellitus, Type 2
The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion.
Diabetes Mellitus, Type 2
The comparison of serum vaspin and visfatin concentrations in obese and normal weight women.
Diabetes Mellitus, Type 2
The correlation between insulin-like growth factor 1 (IGF-1) and novel adipocytokines in postmenopausal women: A population-based study.
Diabetes Mellitus, Type 2
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
Diabetes Mellitus, Type 2
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The Impact of Type 2 Diabetes on Circulating Adipokines in Patients with Metabolic Syndrome.
Diabetes Mellitus, Type 2
The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.
Diabetes Mellitus, Type 2
The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Diabetes Mellitus, Type 2
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
Diabetes Mellitus, Type 2
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Diabetes Mellitus, Type 2
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Diabetes Mellitus, Type 2
Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients.
Diabetes Mellitus, Type 2
Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
Diabetes Mellitus, Type 2
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Diabetes Mellitus, Type 2
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NF?B and JNK in human abdominal subcutaneous adipocytes.
Diabetes Mellitus, Type 2
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Diabetes Mellitus, Type 2
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Diabetes Mellitus, Type 2
Visfatin Stimulates a Cellular Renin-Angiotensin System in Cultured Rat Mesangial Cells.
Diabetes Mellitus, Type 2
Visfatin Triggers Anorexia and Body Weight Loss through Regulating the Inflammatory Response in the Hypothalamic Microglia.
Diabetes Mellitus, Type 2
Visfatin, TNF-alpha and IL-6 mRNA Expression is Increased in Mononuclear Cells from Type 2 Diabetic Women.
Diabetes Mellitus, Type 2
Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.
Diabetes Mellitus, Type 2
Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions.
Diabetes Mellitus, Type 2
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
Diabetes Mellitus, Type 2
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Diabetes Mellitus, Type 2
[Visfatin level after laparoscopic Roux-en-Y gastric bypass surgery in patients with Type 2 diabetes].
Diabetes, Gestational
A clinical research study on the respective relationships between visfatin and human fetuin A and pregnancy outcomes in gestational diabetes mellitus.
Diabetes, Gestational
Adipokines in gestational diabetes.
Diabetes, Gestational
Are adipokines associated with gestational diabetes mellitus?
Diabetes, Gestational
Association between circulating visfatin and gestational diabetes mellitus: a systematic review and meta-analysis.
Diabetes, Gestational
Central visfatin potentiates glucose-stimulated insulin secretion and ?-cell mass without increasing serum visfatin levels in diabetic rats.
Diabetes, Gestational
Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus.
Diabetes, Gestational
Circulating visfatin levels in the second and third trimester of pregnancies with gestational diabetes: a systematic review.
Diabetes, Gestational
Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus.
Diabetes, Gestational
Decreased plasma visfatin concentrations in women with gestational diabetes mellitus.
Diabetes, Gestational
Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance.
Diabetes, Gestational
Gestational diabetes is associated with high energy and saturated fat intakes and with low plasma visfatin and adiponectin levels independent of prepregnancy BMI.
Diabetes, Gestational
Increased visfatin concentrations in women with gestational diabetes mellitus.
Diabetes, Gestational
Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus.
Diabetes, Gestational
Maternal and cord blood apelin, resistin and visfatin levels in gestational diabetes mellitus.
Diabetes, Gestational
Maternal leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha in normal and gestational diabetes.
Diabetes, Gestational
Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus.
Diabetes, Gestational
Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM.
Diabetes, Gestational
Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus.
Diabetes, Gestational
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Diabetes, Gestational
Relationship of maternal serum resistin and visfatin levels with gestational diabetes mellitus.
Diabetes, Gestational
Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus.
Diabetes, Gestational
Serum visfatin concentration is elevated in pregnant women irrespectively of the presence of gestational diabetes.
Diabetes, Gestational
Serum visfatin concentrations in gestational diabetes mellitus and normal pregnancy.
Diabetes, Gestational
The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes.
Diabetes, Gestational
The role of visfatin (PBEF/Nampt) in pregnancy complications.
Diabetes, Gestational
The role of visfatin in pathogenesis of gestational diabetes (GDM).
Diabetes, Gestational
The Role of Visfatin in the Pathogenesis of Gestational Diabetes Mellitus.
Diabetes, Gestational
Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester.
Diabetes, Gestational
Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue.
Diabetes, Gestational
Visfatin in human pregnancy: maternal gestational diabetes vis-Ã -vis neonatal birthweight.
Diabetes, Gestational
Visfatin level and gestational diabetes mellitus: a systematic review and meta-analysis.
Diabetes, Gestational
Visfatin response to glucose is reduced in women with gestational diabetes mellitus.
Diabetes, Gestational
[Correlation between the expression of gastrocolic omentum visfatin mRNA and gestational diabetes mellitus]
Diabetes, Gestational
[Role of visfatin in the pathogenesis of gestational diabetes mellitus and its relationship with insulin resistance].
Diabetes, Gestational
[The expression of visfatin in placenta in women with gestational diabetes mellitus].
Diabetic Cardiomyopathies
Nampt Potentiates Antioxidant Defense in Diabetic Cardiomyopathy.
Diabetic Ketoacidosis
Evaluation of adipokines, adiponectin, visfatin, and omentin, in uncomplicated type I diabetes patients before and after treatment of diabetic ketoacidosis.
Diabetic Nephropathies
Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy.
Diabetic Nephropathies
Advances in the proinflammatory effects of visfatin and its relationship with diabetic kidney disease.
Diabetic Nephropathies
Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes.
Diabetic Nephropathies
Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy.
Diabetic Nephropathies
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Diabetic Nephropathies
Correlation Between Circulating Visfatin and Nitric Oxide Metabolites Levels in Patients With Diabetic Nephropathy.
Diabetic Nephropathies
Determinants of visfatin in type 2 diabetes patients with diabetic kidney disease: Relationship to inflammation, adiposity and undercarboxylated osteocalcin.
Diabetic Nephropathies
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Diabetic Nephropathies
Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory-fibrosis through the NF-?B p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory-fibrosis by inhibiting endogenous Nampt.
Diabetic Nephropathies
Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.
Diabetic Nephropathies
Irisin and Visfatin Predicts Severity of Diabetic Nephropathy.
Diabetic Nephropathies
OS 36-03 E-BOX CpG HYPOMETHYLATION OF NMN-PRODUCING ENZYME NAMPT IN PROXIMAL TUBULES ENABLES CONSTANT SUPPLY OF NMN FROM TUBULES TO GLOMERULI, WHICH IS DISRUPTED IN DIABETIC NEPHROPATHY.
Diabetic Nephropathies
Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients.
Diabetic Nephropathies
Role of Nampt-Sirt6 Axis in Renal Proximal Tubules in Extracellular Matrix Deposition in Diabetic Nephropathy.
Diabetic Nephropathies
Study of Visfatin Level in Type 1 Diabetic Children and Adolescents.
Diabetic Nephropathies
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
Diabetic Nephropathies
The role of visfatin in diabetic nephropathy.
Diabetic Nephropathies
Visfatin is upregulated in type-2 diabetic rats and targets renal cells.
Diabetic Nephropathies
Visfatin levels are decreased in advanced stages of diabetic nephropathy.
Diabetic Nephropathies
Visfatin Stimulates a Cellular Renin-Angiotensin System in Cultured Rat Mesangial Cells.
Diabetic Nephropathies
Visfatin: a new player in mesangial cell physiology and diabetic nephropathy.
Diabetic Neuropathies
Relationship between diabetic polyneuropathy, serum visfatin, and oxidative stress biomarkers.
Diabetic Retinopathy
Expression of visfatin in the diabetic rat retina.
Diabetic Retinopathy
Serum and vitreous levels of visfatin in patients with diabetic retinopathy.
Diabetic Retinopathy
Visfatin promotes angiogenesis of RF/6A cells through upregulation of VEGF/VEGFR-2 under high-glucose conditions.
Dyslipidemias
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Dyslipidemias
Leptin, resistin and visfatin as useful predictors of gestational diabetes mellitus.
Dyslipidemias
Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis.
Dyslipidemias
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Dyslipidemias
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Encephalitis
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Endometrial Hyperplasia
High level of visfatin and the activation of Akt and ERK1/2 signaling pathways are associated with endometrium malignant transformation in polycystic ovary syndrome.
Endometrial Neoplasms
Circulating Serum Level of Visfatin in Patients with Endometrial Cancer.
Endometrial Neoplasms
Clinical significance of serum adiponectin and visfatin levels in endometrial cancer.
Endometrial Neoplasms
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis.
Endometrial Neoplasms
Visfatin concentrations in patients with endometrial cancer.
Endometrial Neoplasms
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Endometrial Neoplasms
Visfatin, a potential biomarker and prognostic factor for endometrial cancer.
Endometrial Neoplasms
[The research advances in the relationship between visfatin and cancer].
Endotoxemia
Distinct effects of Nampt inhibition on mild and severe models of lipopolysaccharide-induced myocardial impairment.
Endotoxemia
Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD.
Endotoxemia
The sensitivity of adipose tissue visfatin mRNA expression to lipopolysaccharide-induced endotoxemia is increased by ovariectomy in female rats.
Epilepsy
Acute Phase Serum Leptin, Adiponectin, Interleukin-6, and Visfatin Are Altered in Chinese Children With Febrile Seizures: A Cross-Sectional Study.
Epilepsy
Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches.
Epilepsy
The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy.
Erectile Dysfunction
The association between plasma visfatin levels and ED.
Esophageal Squamous Cell Carcinoma
Genetic polymorphisms of NAMPT related with susceptibility to esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.
Essential Hypertension
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure.
Essential Hypertension
Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis.
Essential Hypertension
Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients.
Essential Hypertension
[Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female].
Familial Mediterranean Fever
Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis?
Fatty Liver
A nomogram for predicting metabolic steatohepatitis: The combination of NAMPT, RALGDS, GADD45B, FOSL2, RTP3, and RASD1.
Fatty Liver
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease.
Fatty Liver
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.
Fatty Liver
Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity.
Fatty Liver
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
Fatty Liver
Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome.
Fatty Liver
Effect of curcumin on visfatin and zinc-?2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
Fatty Liver
Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.
Fatty Liver
Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing.
Fatty Liver
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Fatty Liver
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Fatty Liver
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
Fatty Liver
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Fatty Liver
Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway.
Fatty Liver
Obesity Potentiates Esophageal Squamous Cell Carcinoma Growth and Invasion by AMPK-YAP Pathway.
Fatty Liver
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Fatty Liver
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Fatty Liver
The adipokines in the pathogenesis and treatment of nonalcoholic fatty liver disease.
Fatty Liver
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Fatty Liver
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Fatty Liver
Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
Fatty Liver
[Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease]
Fatty Liver
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Fatty Liver, Alcoholic
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Fetal Growth Retardation
Perinatal circulating visfatin levels in intrauterine growth restriction.
Fetal Growth Retardation
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
Fetal Growth Retardation
Uteroplacental insufficiency after bilateral uterine artery ligation in the rat: impact on postnatal glucose and lipid metabolism and evidence for metabolic programming of the offspring by sham operation.
Fetal Growth Retardation
[Relationship of adiponectin and visfatin with fetus intrauterine growth]
Fetal Macrosomia
Low placental visfatin expression is related to impaired glycaemic control and fetal macrosmia in pregnancies complicated by type 1 diabetes.
Fetal Macrosomia
[Relationship of adiponectin and visfatin with fetus intrauterine growth]
Fibrosarcoma
Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation.
Frontotemporal Lobar Degeneration
Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration.
Gallstones
Visfatin-a proinflammatory adipokine-in gallstone disease.
Gastritis
Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement.
Gingivitis
Comparative Evaluation of Salivary Visfatin Levels in Healthy and Periodontally Diseased Patients before and after Scaling and Root Planing.
Gingivitis
Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation.
Gingivitis
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
Gingivitis
The Role of Visfatin (Adipocytokine) Biomarker in Oral Health and Diseases among Nonobese Indian Population: A Proteomic Assay.
Gingivitis
Visfatin levels in gingival crevicular fluid and serum before and after non-surgical treatment for periodontal diseases.
Glioblastoma
Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
Glioblastoma
Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Glioblastoma
Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
Glioblastoma
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
Glioblastoma
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.
Glioblastoma
NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
Glioblastoma
Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.
Glioma
Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.
Glioma
Genotype-targeted local therapy of glioma.
Glioma
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Glioma
Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Glioma
Insulin receptor substrate 1 gene expression is strongly up-regulated by HSPB8 silencing in U87 glioma cells.
Glioma
Intracellular NAD(H) levels control motility and invasion of glioma cells.
Glioma
Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
Glioma
Long noncoding RNA GACAT3 promotes glioma progression by sponging miR-135a.
Glioma
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
Glioma
NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation.
Glioma
NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance.
Glioma
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.
Glioma
NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Glioma
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Glioma
Silencing of NAMPT leads to up-regulation of insulin receptor substrate 1 gene expression in U87 glioma cells.
Glioma
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
Glucose Intolerance
ACTIVATION OF HYPOTHALAMIC NPY, AgRP, MC4R, AND IL-6 mRNA LEVELS IN YOUNG LEWIS RATS WITH EARLY-LIFE DIET-INDUCED OBESITY.
Glucose Intolerance
Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
Glucose Intolerance
Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Glucose Intolerance
Gender dimorphic increase in RBP-4 and NGAL in children born after IVF: an epigenetic phenomenon?
Glucose Intolerance
Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment.
Glucose Intolerance
Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice.
Glucose Intolerance
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Glucose Intolerance
Relationship of maternal serum resistin and visfatin levels with gestational diabetes mellitus.
Glucose Intolerance
Serum levels of visfatin and possible interaction with iron parameters in gestational diabetes mellitus.
Glucose Intolerance
Serum visfatin is elevated in Chinese women with polycystic ovary syndrome, but might not be a reliable predictor of their glucose intolerance.
Glucose Intolerance
Short-term effects induced by nicotinamide in ovariectomized females.
Glucose Metabolism Disorders
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Goiter, Nodular
Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies.
Graves Disease
Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Graves Disease
Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies.
Graves Disease
Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Hashimoto Disease
Obesity in autoimmune diseases: not a passive bystander.
Hashimoto Disease
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Head and Neck Neoplasms
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Head and Neck Neoplasms
Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
Hearing Loss
Environmental enrichment modulates silent information regulator 1 (SIRT1) activity to attenuate central presbycusis in a rat model of normal aging.
Heart Arrest
Plasma Adipokines in Patients Resuscitated from Cardiac Arrest: Difference of Visfatin between Survivors and Nonsurvivors.
Heart Failure
Angiotensin II Type-1 Receptor-JAK/STAT Pathway Mediates the Induction of Visfatin in Angiotensin II-Induced Cardiomyocyte Hypertrophy.
Heart Failure
Both gain and loss of Nampt function promote pressure overload-induced heart failure.
Heart Failure
Monocyte-derived extracellular Nampt-dependent biosynthesis of NAD(+) protects the heart against pressure overload.
Heart Failure
Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure.
Heart Failure
Serum concentration of visfatin is decreased in patients with chronic heart failure.
Heart Failure
[Expression and Initial Mechanism of Nicotinamide Phosphoribosyltransferase (NAMPT) in Dilated Cardiomyopathy].
Hematologic Neoplasms
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Hematologic Neoplasms
Nicotinamide phosphoribosyltransferase (NAMPT) activity is essential for survival of resting lymphocytes.
Hematologic Neoplasms
OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
Hematologic Neoplasms
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
Hepatitis
A key role for Pre-B cell colony-enhancing factor in experimental hepatitis.
Hepatitis
Suppression of SIRT1 activity in noncancerous tissues of HCC: possible association with non-B non-C hepatitis pathogenesis.
Hepatitis B
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Hepatitis B
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Hepatitis B
NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis.
Hepatitis B
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
Hepatitis B
The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B.
Hepatitis B, Chronic
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Hepatitis B, Chronic
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Hepatitis B, Chronic
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Hepatitis B, Chronic
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
Hepatitis C
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Hepatitis C
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Hepatitis C, Chronic
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Hepatitis C, Chronic
Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patients.
Hepatitis C, Chronic
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Hepatitis C, Chronic
Preliminary study of the level of visfatin and the relationship with insulin resistance in Chinese patients with chronic hepatitis C.
Hepatitis C, Chronic
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Hepatitis C, Chronic
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
Hepatitis C, Chronic
Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.
Hepatitis C, Chronic
Visfatin serum levels in chronic hepatitis C patients.
Hidradenitis Suppurativa
Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa.
Hidradenitis Suppurativa
Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study.
Hirsutism
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Hirsutism
Plasma Visfatin Levels in Adolescents with Polycystic Ovary Syndrome: A Prospective Case-Control Study.
Hodgkin Disease
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Hyperandrogenism
Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
Hyperandrogenism
Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome.
Hyperandrogenism
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Hyperandrogenism
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Hyperandrogenism
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
Hypercholesterolemia
Hypercholesterolemia induces adipose dysfunction in conditions of obesity and nonobesity.
Hyperglycemia
Combined SIRT3 and SIRT5 deletion is associated with inner retinal dysfunction in a mouse model of type 1 diabetes.
Hyperglycemia
Differences in plasma apelin and visfatin levels between patients with type 1 diabetes mellitus and healthy subjects and response after acute hyperglycemia and insulin administration.
Hyperglycemia
Hyperglycemia-reduced NAD+ biosynthesis impairs corneal epithelial wound healing in diabetic mice.
Hyperglycemia
in vivo Suppression of Visfatin by Oral Glucose Uptake: Evidence for a Novel Incretin-Like Effect by Glucagon-Like Peptide-1 (GLP-1).
Hyperglycemia
Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens.
Hyperglycemia
Leptin Is Associated With Persistence of Hyperglycemia in Acute Pancreatitis: A Prospective Clinical Study.
Hyperglycemia
Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.
Hyperglycemia
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Hyperglycemia
Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients.
Hyperinsulinism
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Hyperinsulinism
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Hyperlipidemias
Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin.
Hyperlipidemias
Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
Hyperlipidemias
Impact of Chicory?Supplemented Diet on HMG?CoA Reductase, Acetyl?CoA Carboxylase, Visfatin and Anti?Oxidant Status in Triton WR?1339?Induced Hyperlipidemia
Hyperlipoproteinemia Type II
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Hyperostosis
Increased serum leptin and visfatin levels in patients with diffuse idiopathic skeletal hyperostosis: a comparative study.
Hyperostosis, Diffuse Idiopathic Skeletal
Increased serum leptin and visfatin levels in patients with diffuse idiopathic skeletal hyperostosis: a comparative study.
Hypersensitivity
CA1 Nampt knockdown recapitulates hippocampal cognitive phenotypes in old mice which nicotinamide mononucleotide improves.
Hypersensitivity
Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells.
Hypertension
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Hypertension
Adipokine Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy.
Hypertension
Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure.
Hypertension
Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients.
Hypertension
Associations of Apelin, Visfatin, and Urinary 8-Isoprostane With Severe Hypertension in African Americans: The MH-GRID Study.
Hypertension
Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats.
Hypertension
Coexistence of obstructive sleep apnea and telomerase activity, concentration of selected adipose tissue hormones and vascular endothelial function in patients with arterial hypertension.
Hypertension
Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension.
Hypertension
Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2?.
Hypertension
In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children.
Hypertension
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
Hypertension
MC4R Variant rs17782313 Associates With Increased Levels of DNAJC27, Ghrelin, and Visfatin and Correlates With Obesity and Hypertension in a Kuwaiti Cohort.
Hypertension
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase.
Hypertension
NAMPT/SIRT1 Attenuate Ang II-Induced Vascular Remodeling and Vulnerability to Hypertension by Inhibiting the ROS/MAPK Pathway.
Hypertension
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.
Hypertension
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Hypertension
Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension.
Hypertension
Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis.
Hypertension
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Hypertension
Visfatin and Cardio-Cerebro-Vascular Disease.
Hypertension
Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis.
Hypertension
Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy.
Hypertension
Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients.
Hypertension
Visfatin, a potential biomarker and prognostic factor for endometrial cancer.
Hypertension
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
Hypertension
[Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female].
Hypertension, Pregnancy-Induced
Adipokine Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy.
Hypertension, Pregnancy-Induced
Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.
Hypertension, Pregnancy-Induced
Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Hypertension, Pulmonary
Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2?.
Hypertension, Pulmonary
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase.
Hypertension, Pulmonary
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.
Hypertension, Renovascular
Decreased immunoreactivity of visfatin in the pancreas and liver of rats with renovascular hypertension.
Hyperthyroidism
Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Hyperthyroidism
Effect of restoration of euthyroidism on visfatin concentrations and body composition in women.
Hyperthyroidism
Insulin resistance and its correlation with chemerin and visfatin in Saudi patients with hyperthyroidism.
Hyperthyroidism
Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalisation of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
Hyperthyroidism
The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin.
Hyperthyroidism
Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations.
Hyperthyroidism
Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Hyperthyroidism
Visfatin, PON-1 Levels in Iraqi Hyperthyroidism Patient's with Dyslipidemia.
Hypertriglyceridemia
Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients.
Hypertriglyceridemia
Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.
Hypertrophy, Left Ventricular
Reduced visfatin levels in aortic stenosis increase after aortic valve replacement and may contribute to reverse left ventricular remodelling.
Hypertrophy, Left Ventricular
The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Hypertrophy, Left Ventricular
The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients.
Hypertrophy, Left Ventricular
Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy.
Hypoglycemia
The effect of sitagliptin on obese patients with insulin treatment-induced diabetes mellitus.
Hypophosphatemia
Hepatectomy-related hypophosphatemia: a novel phosphaturic factor in the liver-kidney axis.
Hypophosphatemia
Hypophosphatemia after Hepatectomy or Pancreatectomy: Role of the Nicotinamide Phosphoribosyltransferase.
Hypothyroidism
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Hypothyroidism
Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalisation of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
Hypothyroidism
Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation mechanism between visfatin and tri-iodothyronine with various concentrations.
Hypothyroidism
Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Hypothyroidism
Visfatin, Leptin, and TNF-?: Interrelated Adipokines in Insulin-Resistant Clinical and Subclinical Hypothyroidism.
Immune System Diseases
An elevated plasma level of visfatin increases the risk of myocardial infarction.
Immune System Diseases
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders.
Immune System Diseases
Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis.
Infarction, Middle Cerebral Artery
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
Infarction, Middle Cerebral Artery
Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade.
Infections
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Infections
Adenovirus36 infection expresses cellular APMI and Visfatin genes in overweight Uygur individuals.
Infections
Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.
Infections
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Infections
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Infections
Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Infections
Genetic Profiling and Comorbidities of Zika Infection.
Infections
Inhibition of pre-B cell colony-enhancing factor (PBEF/NAMPT/visfatin) decreases the ability of human neutrophils to generate reactive oxidants but does not impair bacterial killing.
Infections
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Infections
Intracellular survival of Staphylococcus aureus in adipocyte-like differentiated 3T3-L1 cells is glucose dependent and alters cytokine, chemokine, and adipokine secretion.
Infections
Maternal plasma visfatin in preterm labor.
Infections
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Infections
Nicotinamide phosphoribosyltransferase and intra-amniotic inflammation in preterm prelabor rupture of membranes.
Infections
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Infections
Pre-B-cell colony-enhancing factor (PBEF/Visfatin) gene expression is modulated by NF-kappaB and AP-1 in human amniotic epithelial cells.
Infections
Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes.
Infections
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Infections
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
Infections
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
Infections
Visfatin regulates the terminal processes of human labour and delivery via activation of the nuclear factor-?B pathway.
Infections
Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.
Infections
Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.
Infections
Weighted Gene Co-Expression Network Analysis Identifies Key Modules and Hub Genes Associated with Mycobacterial Infection of Human Macrophages.
Inflammatory Bowel Diseases
Adipocytokines: The pied pipers.
Inflammatory Bowel Diseases
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Inflammatory Bowel Diseases
Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients.
Inflammatory Bowel Diseases
Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
Inflammatory Bowel Diseases
Obesity in autoimmune diseases: not a passive bystander.
Inflammatory Bowel Diseases
Serum Visfatin Levels in Ulcerative Colitis.
Inflammatory Bowel Diseases
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Influenza, Human
Puerarin reduces impairment of intestinal and adipose immune responses to influenza virus infection in mice.
Insulin Resistance
A novel single-nucleotide polymorphism of the visfatin gene and its associations with performance traits in the chicken.
Insulin Resistance
A single bout of downhill running transiently increases HOMA-IR without altering adipokine response in healthy adult women.
Insulin Resistance
ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity.
Insulin Resistance
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Insulin Resistance
Adipocytokines and bone mineral density in adolescent female athletes.
Insulin Resistance
Adipocytokines and the metabolic complications of obesity.
Insulin Resistance
Adipokines and ?-cell dysfunction in normoglycemic women with previous gestational diabetes mellitus.
Insulin Resistance
Adipokines and cardiometabolic function: How are they interlinked?
Insulin Resistance
Adipokines and etiopathology of metabolic disorders.
Insulin Resistance
Adipokines and insulin resistance.
Insulin Resistance
Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis.
Insulin Resistance
Adiponectin and visfatin levels in extremely low birth weight infants; they are also at risk for insulin resistance.
Insulin Resistance
Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea.
Insulin Resistance
Adipose tissue and its role in organ crosstalk.
Insulin Resistance
Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment.
Insulin Resistance
Aerobic exercise training-induced decrease in plasma visfatin and insulin resistance in obese female adolescents.
Insulin Resistance
Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease.
Insulin Resistance
An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity.
Insulin Resistance
Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance.
Insulin Resistance
Are plasma levels of visfatin and retinol-binding protein 4 (RBP4) associated with body mass, metabolic and hormonal disturbances in women with polycystic ovary syndrome?
Insulin Resistance
Association of adipokines with obesity in children and adolescents.
Insulin Resistance
Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis Vulgaris.
Insulin Resistance
Association of Apolipoprotein E Polymorphism with Adipokines and Cardiovascular Disease Risk in Rheumatoid Arthritis Patients.
Insulin Resistance
Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.
Insulin Resistance
Association of circulating visfatin concentrations with insulin resistance and low-grade inflammation after dietary energy restriction in Spanish obese non-diabetic women: Role of body composition changes.
Insulin Resistance
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Insulin Resistance
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Insulin Resistance
Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity.
Insulin Resistance
C358A missense polymorphism of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) and visfatin levels in obese females.
Insulin Resistance
Central visfatin potentiates glucose-stimulated insulin secretion and ?-cell mass without increasing serum visfatin levels in diabetic rats.
Insulin Resistance
Change of visfatin, C-reactive protein concentrations, and insulin sensitivity in patients with hyperthyroidism.
Insulin Resistance
Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
Insulin Resistance
Changes in Serum Nampt Levels and Its Significances in Diabetic Nephropathy Patients-The Potential Role of Nampt in T2DM with Diabetic Nephropathy.
Insulin Resistance
Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus.
Insulin Resistance
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Insulin Resistance
Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus.
Insulin Resistance
Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes.
Insulin Resistance
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome.
Insulin Resistance
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Insulin Resistance
Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle.
Insulin Resistance
Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Insulin Resistance
Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
Insulin Resistance
Circulating visfatin levels in healthy preterm infants are independently associated with high-density lipoprotein cholesterol levels and dietary long-chain polyunsaturated fatty acids.
Insulin Resistance
Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
Insulin Resistance
Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification.
Insulin Resistance
Correlation of serum adipocytokine levels with glycolipid metabolism and inflammatory factors in obese patients with periodontal disease.
Insulin Resistance
Correlations between the expression of the insulin sensitizing hormones, adiponectin, visfatin, and omentin, and the appetite regulatory hormone, neuropeptide Y and its receptors in subcutaneous and visceral adipose tissues.
Insulin Resistance
Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus.
Insulin Resistance
CTRP3 modulates the expression and secretion of adipokines in 3T3-L1 adipocytes.
Insulin Resistance
Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes.
Insulin Resistance
Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome.
Insulin Resistance
Dietary Blueberry and Soluble Fiber Improve Serum Antioxidant and Adipokine Biomarkers and Lipid Peroxidation in Pregnant Women with Obesity and at Risk for Gestational Diabetes.
Insulin Resistance
Differences in Metabolic Factors Between Antipsychotic-Induced Weight Gain and Non-pharmacological Obesity in Youths.
Insulin Resistance
Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function.
Insulin Resistance
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Insulin Resistance
Effect of oncological treatment on serum adipocytokine levels in patients with stage II-III breast cancer.
Insulin Resistance
Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
Insulin Resistance
Effect of postprandial lipemia on plasma concentrations of A-FABP, RBP-4 and visfatin.
Insulin Resistance
Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Insulin Resistance
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Insulin Resistance
Effect of restoration of euthyroidism on visfatin concentrations and body composition in women.
Insulin Resistance
Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Insulin Resistance
Effect of substituting saturated with monounsaturated fatty acids on serum visfatin levels and insulin resistance in overweight women: A randomized cross-over clinical trial.
Insulin Resistance
Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
Insulin Resistance
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Insulin Resistance
Effects of different levels of physical inactivity on plasma visfatin in healthy normal-weight men.
Insulin Resistance
Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats.
Insulin Resistance
Effects of fatty acid regulation on visfatin gene expression in adipocytes.
Insulin Resistance
Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children.
Insulin Resistance
Effects of high-fat high-sucrose feeding, energy restriction, and trans-10,cis-12 conjugated linoleic acid on visfatin and apelin in hamsters.
Insulin Resistance
Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
Insulin Resistance
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Insulin Resistance
Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: A 48-week comparative study.
Insulin Resistance
Effects of visfatin gene polymorphism RS4730153 on exercise-induced weight loss of obese children and adolescents of Han Chinese.
Insulin Resistance
Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes.
Insulin Resistance
Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance.
Insulin Resistance
Elevated visfatin levels in obese children are related to proinflammatory factors.
Insulin Resistance
Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.
Insulin Resistance
Estrogens induce visfatin expression in 3T3-L1 cells.
Insulin Resistance
Evaluation of adipocytokines in obese children with insulin resistance.
Insulin Resistance
Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
Insulin Resistance
Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome.
Insulin Resistance
Evidence for serum visfatin but not adiponectin or resistin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
Insulin Resistance
Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome.
Insulin Resistance
Extracellular Visfatin Activates Gluconeogenesis in HepG2 Cells Through the Classical PKA/CREB-Dependent Pathway.
Insulin Resistance
Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population.
Insulin Resistance
Glucagon-like Peptide-1 Upregulates Visfatin Expression in 3T3-L1 Adipocytes.
Insulin Resistance
High birth weight and early postnatal weight gain protect obese children and adolescents from truncal adiposity and insulin resistance: metabolically healthy but obese subjects?
Insulin Resistance
Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment.
Insulin Resistance
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Insulin Resistance
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Insulin Resistance
Impact of Low Frequency Electro-acupuncture on Glucose and Lipid Metabolism in Unmarried PCOS Women: A Randomized Controlled Trial.
Insulin Resistance
Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease.
Insulin Resistance
Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome.
Insulin Resistance
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Insulin Resistance
Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Insulin Resistance
Importance of Adipose Tissue NAD+ Biology in Regulating Metabolic Flexibility.
Insulin Resistance
Increase in visfatin after weight loss induced by gastroplastic surgery.
Insulin Resistance
Increased insulin sensitivity in individuals with neurofibromatosis type 1.
Insulin Resistance
Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.
Insulin Resistance
Increased visfatin concentrations in women with gestational diabetes mellitus.
Insulin Resistance
Increased visfatin in hemodialysis patients is associated with decreased demands for recombinant human erythropoietin.
Insulin Resistance
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Insulin Resistance
Insulin resistance and its correlation with chemerin and visfatin in Saudi patients with hyperthyroidism.
Insulin Resistance
Insulin resistance, serum visfatin, and adiponectin levels are associated with metabolic disorders in chronic hepatitis C virus-infected patients.
Insulin Resistance
Intensive glycemic control lowers plasma visfatin levels in patients with type 2 diabetes.
Insulin Resistance
Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors.
Insulin Resistance
Intrauterine Growth Restriction: the controversial role of perinatal adipocytokines in the prediction of metabolic adult disease.
Insulin Resistance
Lack of effect of a moderate hypocaloric diet on visfatin levels in morbid obese patients: relationship with insulin resistance.
Insulin Resistance
Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease.
Insulin Resistance
Long-term high-fat diet links the regulation of the insulin-sensitizing fibroblast growth factor-21 and visfatin.
Insulin Resistance
Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery.
Insulin Resistance
Macrostemonoside A promotes visfatin expression in 3T3-L1 cells.
Insulin Resistance
Maternal plasma visfatin in preterm labor.
Insulin Resistance
Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus.
Insulin Resistance
Maternal visfatin concentration in normal pregnancy.
Insulin Resistance
Mechanisms involved in altered bone metabolism in diabetes: a narrative review.
Insulin Resistance
Molecular characteristics of serum visfatin and differential detection by immunoassays.
Insulin Resistance
Monomeric eNAMPT in the development of experimental diabetes in mice: a potential target for type 2 diabetes treatment.
Insulin Resistance
mRNA abundance of adiponectin and its receptors, leptin and visfatin and of G-protein coupled receptor 41 in five different fat depots from sheep.
Insulin Resistance
NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat-induced insulin resistance.
Insulin Resistance
NAMPT-Mediated NAD(+) Biosynthesis in Adipocytes Regulates Adipose Tissue Function and Multi-organ Insulin Sensitivity in Mice.
Insulin Resistance
Nicotinamide phosphoribosyltransferase enhances beta cell expansion during pregnancy.
Insulin Resistance
Novel effects of macrostemonoside A, a compound from Allium macrostemon Bung, on hyperglycemia, hyperlipidemia, and visceral obesity in high-fat diet-fed C57BL/6 mice.
Insulin Resistance
Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.
Insulin Resistance
Obesity and obstructive sleep apnea syndrome.
Insulin Resistance
Obesity Is Associated With Low NAD(+)/SIRT Pathway Expression in Adipose Tissue of BMI-Discordant Monozygotic Twins.
Insulin Resistance
Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome.
Insulin Resistance
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
Insulin Resistance
Perinatal circulating visfatin levels in intrauterine growth restriction.
Insulin Resistance
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Insulin Resistance
Placental expressions and serum levels of adiponectin, visfatin, and omentin in GDM.
Insulin Resistance
Plasma levels of lipopolysaccharide correlate with insulin resistance in HIV patients.
Insulin Resistance
Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
Insulin Resistance
Plasma visfatin and adiponectin concentrations in physically active adolescent girls: relationships with insulin sensitivity and body composition variables.
Insulin Resistance
Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome.
Insulin Resistance
Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children.
Insulin Resistance
Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.
Insulin Resistance
Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices.
Insulin Resistance
Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalisation of thyroid function and are not related to insulin resistance, anthropometric or inflammatory parameters.
Insulin Resistance
Plasma visfatin is increased after high-intensity exercise.
Insulin Resistance
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Insulin Resistance
Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome.
Insulin Resistance
Portal and systemic levels of visfatin in morbidly obese subjects undergoing bariatric surgery.
Insulin Resistance
Preliminary study of the level of visfatin and the relationship with insulin resistance in Chinese patients with chronic hepatitis C.
Insulin Resistance
Prothrombotic state, cardiovascular, and metabolic syndrome risk factors in prepubertal children born large for gestational age.
Insulin Resistance
Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
Insulin Resistance
Regulation of adipokine secretion by n-3 fatty acids.
Insulin Resistance
Relation of chemokines to BMI and insulin resistance at ages 18-21.
Insulin Resistance
Relationship between 11?-HSD2 mRNA and insulin sensitivity in term small-for-gestational age neonates after birth.
Insulin Resistance
Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans.
Insulin Resistance
Relationship of visfatin level to pancreatic endocrine hormone level, HOMA-IR index, and HOMA ?-cell index in overweight women who performed hydraulic resistance exercise.
Insulin Resistance
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Insulin Resistance
Resistin, visfatin and insulin sensitivity in selected phases of annual training cycle of triathletes.
Insulin Resistance
Resistin, visfatin, leptin and omentin are differently related to hormonal and metabolic parameters in growth hormone-deficient children.
Insulin Resistance
Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Insulin Resistance
Secretory function of adipose tissue.
Insulin Resistance
Serum concentration of visfatin is decreased in patients with chronic heart failure.
Insulin Resistance
Serum levels of the adipokine visfatin are increased in pre-eclampsia.
Insulin Resistance
Serum levels of visfatin, resistin and adiponectin in patients with psoriatic arthritis and associations with disease severity.
Insulin Resistance
Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome.
Insulin Resistance
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Insulin Resistance
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Insulin Resistance
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
Insulin Resistance
Serum visfatin concentration and its relationship with sex hormones in obese Saudi women.
Insulin Resistance
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Insulin Resistance
Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol.
Insulin Resistance
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Insulin Resistance
Serum visfatin in Asian women with polycystic ovary syndrome.
Insulin Resistance
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Insulin Resistance
Serum Visfatin Increases With Progressive {beta}-Cell Deterioration.
Insulin Resistance
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Insulin Resistance
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Insulin Resistance
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa.
Insulin Resistance
Serum visfatin levels in women with polycystic ovary syndrome.
Insulin Resistance
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Insulin Resistance
Serum visfatin, resistin and IL-18 in A group of Egyptian obese diabetic and non diabetic individuals.
Insulin Resistance
Short-term regulation of Visfatin release in vivo by oral lipid ingestion and in vitro by fatty acid stimulation.
Insulin Resistance
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
Insulin Resistance
Skeletal muscle overexpression of nicotinamide phosphoribosyl transferase in mice coupled with voluntary exercise augments exercise endurance.
Insulin Resistance
Sleep Deficiency is a Modifiable Risk Factor for Obesity and Cognitive Impairment and Associated with Elevated Visfatin.
Insulin Resistance
Spleen-yang-deficiency patients with polycystic ovary syndrome have higher levels of visfatin.
Insulin Resistance
The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo.
Insulin Resistance
The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile.
Insulin Resistance
The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus.
Insulin Resistance
The effects of genistein supplementation on fructose induced insulin resistance, oxidative stress and inflammation.
Insulin Resistance
The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus.
Insulin Resistance
The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing.
Insulin Resistance
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
Insulin Resistance
The metabolic syndrome: metabolic changes with vascular consequences.
Insulin Resistance
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
Insulin Resistance
The relationship between serum visfatin, adiponectin, and insulin sensitivity markers in neonates after birth.
Insulin Resistance
The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance.
Insulin Resistance
The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients.
Insulin Resistance
The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity.
Insulin Resistance
The role of adipokines in skeletal muscle inflammation and insulin sensitivity.
Insulin Resistance
The role of adipokines in the pathogenesis of gestational diabetes mellitus.
Insulin Resistance
The role of infiltrating immune cells in dysfunctional adipose tissue.
Insulin Resistance
The role of leptin, soluble leptin receptor, adiponectin and visfatin in insulin sensitivity in preterm born children in prepubertal ages.
Insulin Resistance
The role of the adipocytokines vaspin and visfatin in vascular endothelial function and insulin resistance in obese children.
Insulin Resistance
The up-regulation of markers of adipose tissue fibrosis by visfatin in pre-adipocytes as well as obese children and adolescents.
Insulin Resistance
The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis.
Insulin Resistance
The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects.
Insulin Resistance
Therapeutic perspectives of adipocytokines.
Insulin Resistance
TNF-alpha alters visfatin and adiponectin levels in human fat.
Insulin Resistance
Transition period-related changes in the abundance of the mRNAs of adiponectin and its receptors, of visfatin, and of fatty acid binding receptors in adipose tissue of high-yielding dairy cows.
Insulin Resistance
Visceral fat resection in humans: Effect on insulin sensitivity, beta-cell function, adipokines and inflammatory markers.
Insulin Resistance
Visfatin (Nampt) and Ghrelin as Novel Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes.
Insulin Resistance
VISFATIN (NAMPT) Improves In Vitro IGF1-Induced Steroidogenesis and IGF1 Receptor Signaling Through SIRT1 in Bovine Granulosa Cells.
Insulin Resistance
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Insulin Resistance
Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis.
Insulin Resistance
Visfatin and insulin levels and cigarette smoking are independent risk factors for hidradenitis suppurativa: a case-control study.
Insulin Resistance
Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation.
Insulin Resistance
Visfatin and retinol-binding protein 4 concentrations in lean, glucose-tolerant women with PCOS.
Insulin Resistance
Visfatin and SREBP-1c mRNA Expressions and Serum Levels Among Egyptian Women with Polycystic Ovary Syndrome.
Insulin Resistance
Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester.
Insulin Resistance
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Insulin Resistance
Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients.
Insulin Resistance
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Insulin Resistance
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Insulin Resistance
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Insulin Resistance
Visfatin Induces Inflammation and Insulin Resistance via the NF-?B and STAT3 Signaling Pathways in Hepatocytes.
Insulin Resistance
Visfatin inhibits apoptosis of pancreatic {beta}-cell line, MIN6, via the mitogen-activated protein kinase/phosphoinositide 3-kinase pathway.
Insulin Resistance
Visfatin is an adipokine, but it is not regulated by thiazolidinediones.
Insulin Resistance
Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
Insulin Resistance
Visfatin is involved in TNF?-mediated insulin resistance via an NAD(+)/Sirt1/PTP1B pathway in 3T3-L1 adipocytes.
Insulin Resistance
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Insulin Resistance
Visfatin is upregulated in type-2 diabetic rats and targets renal cells.
Insulin Resistance
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Insulin Resistance
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Insulin Resistance
Visfatin regulates genes related to lipid metabolism in porcine adipocytes.
Insulin Resistance
Visfatin serum concentration and hepatic mRNA expression in chronic hepatitis C.
Insulin Resistance
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Insulin Resistance
Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
Insulin Resistance
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Insulin Resistance
Visfatin, TNF-alpha and IL-6 mRNA Expression is Increased in Mononuclear Cells from Type 2 Diabetic Women.
Insulin Resistance
Visfatin: a new player in mesangial cell physiology and diabetic nephropathy.
Insulin Resistance
Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study.
Insulin Resistance
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
Insulin Resistance
[Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome]
Insulin Resistance
[Effect of flavonoids from Abelmoschus manihot on proliferation, differentiation of 3T3-L1 preadipocyte and insulin resistance].
Insulin Resistance
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
Insulin Resistance
[Effects of visfatin gene overexpression on insulin sensitivity in the insulin-resistant rats induced by high-fat diet]
Insulin Resistance
[Inflammatory biomarkers: the link between obesity and associated pathologies]
Insulin Resistance
[New evidence for the pathogenesis of obesity: adipokines are adipose tissue hormone].
Insulin Resistance
[Novel adipokines: links between obesity and atherosclerosis].
Insulin Resistance
[Resistin: a pathogenic factor or a biomarker of metabolic disorders and inflammation?]
Insulin Resistance
[Role of visfatin in the pathogenesis of gestational diabetes mellitus and its relationship with insulin resistance].
Insulin Resistance
[The research advances in the relationship between visfatin and cancer].
Insulin Resistance
[Visfatin in obese patients, relation with cardiovascular risk factors, a cross sectional study.]
Insulin Resistance
[Visfatin level after laparoscopic Roux-en-Y gastric bypass surgery in patients with Type 2 diabetes].
Insulin Resistance
[Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans.]
Insulin Resistance
[Visfatin promotes production of monocyte chemotactic protein-1 and interleukin-6 in human endothelial cells via insulin receptor]
Insulinoma
Visfatin Protects Rat Pancreatic ?-cells against IFN-?-Induced Apoptosis through AMPK and ERK1/2 Signaling Pathways.
Intervertebral Disc Degeneration
Small Extracellular Vesicles Derived from Adipocytes Attenuate Intervertebral Disc Degeneration in Rats by Rejuvenating Senescent Nucleus Pulposus Cells and Endplate Cells by Delivering Exogenous NAMPT.
Intervertebral Disc Degeneration
Visfatin promotes intervertebral disc degeneration by inducing IL-6 expression through the ERK/JNK/p38 signalling pathways.
Intracranial Aneurysm
Relationsh?p of spontaneous subarachnoid haemorrhage and cerebral aneurysm to serum Visfatin and Nesfatin-1 levels.
Ischemic Stroke
Adipokines in neurovascular diseases.
Ischemic Stroke
Association of serum vaspin, apelin, and visfatin levels and stroke risk in a Chinese case-control study.
Ischemic Stroke
Change in plasma visfatin level after severe traumatic brain injury.
Ischemic Stroke
Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke.
Ischemic Stroke
Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia.
Ischemic Stroke
NAMPT as a Therapeutic Target against Stroke.
Ischemic Stroke
Neuronal NAMPT is released after cerebral ischemia and protects against white matter injury.
Ischemic Stroke
Neuroprotective Efficacy of an Aminopropyl Carbazole Derivative P7C3-A20 in Ischemic Stroke.
Ischemic Stroke
Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway.
Ischemic Stroke
Notoginsenoside R1 activates the NAMPT-NAD+-SIRT1 cascade to promote postischemic angiogenesis by modulating Notch signaling.
Ischemic Stroke
Pre-B-cell colony-enhancing factor protects against apoptotic neuronal death and mitochondrial damage in ischemia.
Ischemic Stroke
Prognostic significance of plasma visfatin levels in patients with ischemic stroke.
Ischemic Stroke
Regenerative Neurogenesis After Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase-Nicotinamide Adenine Dinucleotide Cascade.
Ischemic Stroke
Selected adipose tissue hormones in the blood of patients with ischaemic cerebral stroke.
Ischemic Stroke
Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis.
Ischemic Stroke
Visfatin and Cardio-Cerebro-Vascular Disease.
Joint Diseases
Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases.
Kidney Diseases
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Kidney Diseases
Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients.
Kidney Failure, Chronic
Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol.
Kidney Failure, Chronic
Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Kidney Neoplasms
Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Leiomyoma
Differential expression of visfatin, leptin, stromal cell derived factor-1?, endothelial nitric oxide synthase, and vascular endothelial growth factor in human leiomyomas.
Leiomyoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Leiomyosarcoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Leukemia
APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
Leukemia
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Leukemia
Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
Leukemia
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
Leukemia
NAD as a genotype-specific drug target.
Leukemia
NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.
Leukemia
Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.
Leukemia
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
Leukemia
The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.
Leukemia
Visfatin concentrations in children with leukemia before and after stem cell transplantation.
Leukemia, Lymphocytic, Chronic, B-Cell
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Suppression of NAMPT expression enhances the sensitivity of K562 cells to imatinib and its relative mechanism].
Leukemia, Myeloid
The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.
Leukemia, Myeloid, Acute
Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Leukemia, Myeloid, Acute
The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells.
Leukemia, Myeloid, Acute
Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL-17.
Liver Cirrhosis
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Liver Cirrhosis
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Liver Cirrhosis
Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
Liver Cirrhosis
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Liver Cirrhosis
Splanchnic concentrations and postprandial release of visceral adipokines.
Liver Cirrhosis
The Effectiveness of Mediterranean Diet in Nonalcoholic Fatty Liver Disease Clinical Course: An Intervention Study.
Liver Cirrhosis
The Possible Role of Adipokines in HCV Associated Hepatocellular Carcinoma.
Liver Cirrhosis
The relationship between serum visfatin and the progress of chronic viral hepatitis B cirrhosis.
Liver Cirrhosis
Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
Liver Cirrhosis
[Effect of visfatin on the expression of basic fibroblast growth factor in rat hepatic stellate cells]
Liver Cirrhosis, Alcoholic
Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis.
Liver Cirrhosis, Biliary
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Liver Diseases
A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study.
Liver Diseases
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease.
Liver Diseases
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.
Liver Diseases
Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.
Liver Diseases
Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity.
Liver Diseases
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
Liver Diseases
Effect of curcumin on visfatin and zinc-?2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
Liver Diseases
Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.
Liver Diseases
Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.
Liver Diseases
Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
Liver Diseases
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Liver Diseases
Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease.
Liver Diseases
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Liver Diseases
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
Liver Diseases
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Liver Diseases
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Liver Diseases
Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway.
Liver Diseases
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Liver Diseases
Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
Liver Diseases
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Liver Diseases
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Liver Diseases
Serum visfatin in nonalcoholic fatty liver disease.
Liver Diseases
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Liver Diseases
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Liver Diseases
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.
Liver Diseases
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Liver Diseases
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Liver Diseases
Visfatin Induces Inflammation and Insulin Resistance via the NF-?B and STAT3 Signaling Pathways in Hepatocytes.
Liver Diseases
Visfatin levels in nonalcoholic Fatty liver disease.
Liver Diseases
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Liver Diseases
[Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease]
Liver Diseases
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Liver Diseases, Alcoholic
NAMPT overexpression alleviates alcohol-induced hepatic steatosis in mice.
Liver Neoplasms
Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells.
Liver Neoplasms
Inhibition of PI3K/Akt and ERK signaling decreases visfatin-induced invasion in liver cancer cells.
Liver Neoplasms
NAMPT promotes hepatitis B virus replication and liver cancer cell proliferation through the regulation of aerobic glycolysis.
Liver Neoplasms
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Liver Neoplasms
The role of Visfatin and Resistin in an In Vitro Model of Obesity-Induced Invasive Liver Cancer.
Lung Diseases
Serum Adipokine Levels in Patients Considered for Lung Transplantation.
Lung Diseases
Serum Levels of Visfatin, Omentin and Irisin in Patients with End-Stage Lung Disease Before and After Lung Transplantation.
Lung Injury
Endothelial eNAMPT Amplifies Preclinical Acute Lung Injury: Efficacy of an eNAMPT-Neutralising mAb.
Lung Injury
Inhibition of Pre-B Cell Colony Enhancing Factor Reduces Lung Injury in Rats Receiving Cardiopulmonary Bypass.
Lung Injury
Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralization.
Lung Injury
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.
Lung Injury
Targeting of nicotinamide phosphoribosyltransferase enzymatic activity ameliorates lung damage induced by ischemia/reperfusion in rats.
Lung Injury
The NAMPT Promoter is Regulated by Mechanical Stress, STAT5, and ARDS-Associated Genetic Variants.
Lung Injury
Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NF?B Signaling and Inflammatory Lung Injury.
Lung Injury
Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown.
Lung Injury
Visfatin Exerts Immunotherapeutic Effects in Lipopolysaccharide-Induced Acute Lung Injury in Murine Model.
Lung Neoplasms
An RNA-binding-protein, NONO governs energy metabolism by regulating NAMPT in lung cancer.
Lung Neoplasms
Evaluation of Serum Resistin, Visfatin, and Chemerin Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease.
Lung Neoplasms
NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Lung Neoplasms
Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Lung Neoplasms
Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Lung Neoplasms
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Lung Neoplasms
The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer.
Lung Neoplasms
Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
Lung Neoplasms
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Lupus Erythematosus, Systemic
Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases.
Lupus Erythematosus, Systemic
Obesity in autoimmune diseases: not a passive bystander.
Lupus Erythematosus, Systemic
Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis.
Lupus Erythematosus, Systemic
The comparison of visfatin levels of gingival crevicular fluid in systemic lupus erythematosus and chronic periodontitis patients with healthy subjects.
Lupus Erythematosus, Systemic
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Lymphatic Metastasis
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
Lymphatic Metastasis
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Lymphatic Metastasis
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Lymphatic Metastasis
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Lymphatic Metastasis
Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis.
Lymphatic Metastasis
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis.
Lymphatic Metastasis
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Lymphatic Metastasis
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Lymphohistiocytosis, Hemophagocytic
Pre-B-cell colony-enhancing factor is markedly elevated in childhood hemophagocytic lymphohistiocytosis.
Lymphoma
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Lymphoma, B-Cell
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Lymphoma, B-Cell
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Lymphoma, Follicular
Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
Lymphoma, T-Cell, Cutaneous
Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.
Lymphopenia
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Macular Edema
Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions.
Malnutrition
Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
Malnutrition
Role of circulating adipocytokines vaspin, apelin, and visfatin in the loss of appetite in underweight children: a pilot trial.
Malnutrition
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa.
Melanoma
A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.
Melanoma
Anti-angiogenic role of microRNA-23b in melanoma by disturbing NF-?B signaling pathway via targeted inhibition of NAMPT.
Melanoma
Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma ME45 cells.
Melanoma
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
Melanoma
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Melanoma
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.
Melanoma
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
Melanoma
Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions.
Melanoma
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.
Melanoma
Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Melanoma
Sebocytes differentially express and secrete adipokines.
Melanoma
Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT).
Melanoma
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5).
Melanoma
The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells.
Melanoma
Viability and oxidative response of human colorectal HCT-116 cancer cells treated with visfatin/eNampt in vitro.
Melanoma
Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study.
Melanoma
[Key role of nicotinamide phosphoribosyltransferase (NAMPT) and NAD metabolism in the transition of melanoma cells to an invasive and drug-resistant phenotype].
Melanoma, Experimental
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5).
Memory Disorders
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Mesenteric Ischemia
The effect of serum, intestinal and peritoneal visfatin levels on early diagnosis of acute mesenteric ischemia.
Metabolic Diseases
Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes.
Metabolic Diseases
Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors.
Metabolic Diseases
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.
Metabolic Diseases
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Metabolic Diseases
The mRNA Expression and Circulating Levels of Visfatin and Their Correlation with Coronary Artery Disease Severity and 25-Hydroxyvitamin D.
Metabolic Diseases
Tripeptide IRW Upregulates NAMPT Protein Levels in Cells and Obese C57BL/6J Mice.
Metabolic Diseases
Visfatin as a novel mediator released by inflamed human endothelial cells.
Metabolic Diseases
Visfatin Triggers Anorexia and Body Weight Loss through Regulating the Inflammatory Response in the Hypothalamic Microglia.
Metabolic Diseases
Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders.
Metabolic Syndrome
Adipokines and cardiometabolic function: How are they interlinked?
Metabolic Syndrome
Adiponectin and visfatin may serve as diagnosis markers for metabolic syndrome in Uygur population.
Metabolic Syndrome
An evaluation of visfatin levels in obese subjects.
Metabolic Syndrome
Apelin, vaspin, visfatin and adiponectin in large for gestational age infants with insulin resistance.
Metabolic Syndrome
Assessment of Metabolic Profile and Ischemia-modified Albumin Level in Patients with Alopecia Areata: A Case-Control Study.
Metabolic Syndrome
Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities.
Metabolic Syndrome
Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome.
Metabolic Syndrome
Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome.
Metabolic Syndrome
Circulating visfatin levels in healthy preterm infants are independently associated with high-density lipoprotein cholesterol levels and dietary long-chain polyunsaturated fatty acids.
Metabolic Syndrome
Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis.
Metabolic Syndrome
Correlation of visfatin level with non-alcoholic fatty liver in metabolic syndrome.
Metabolic Syndrome
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Metabolic Syndrome
Effects of 12 weeks of combined exercise training on visfatin and metabolic syndrome factors in obese middle-aged women.
Metabolic Syndrome
Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.
Metabolic Syndrome
Evaluation of irisin and visfatin levels in very low birth weight preterm newborns compared to full term newborns-A prospective cohort study.
Metabolic Syndrome
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Metabolic Syndrome
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Metabolic Syndrome
Hypothalamic ischemia and metabolic syndrome Comment to: Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Jerzy BeÅtowski Med Sci Monit, 2006; 12(6): RA112-19.
Metabolic Syndrome
Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Metabolic Syndrome
Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Metabolic Syndrome
Increased plasma visfatin levels in subjects with the metabolic syndrome.
Metabolic Syndrome
Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.
Metabolic Syndrome
Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-? antagonist therapy.
Metabolic Syndrome
Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin.
Metabolic Syndrome
Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls.
Metabolic Syndrome
Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome.
Metabolic Syndrome
Relation of Adiponectin, Visfatin and Bone Mineral Density in patients with Metabolic Syndrome.
Metabolic Syndrome
Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.
Metabolic Syndrome
Relationship between blood peroxidases activity and visfatin levels in metabolic syndrome patients.
Metabolic Syndrome
Relationship between serum retinol-binding protein 4 and visfatin and the metabolic syndrome.
Metabolic Syndrome
Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Metabolic Syndrome
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Metabolic Syndrome
Serum visfatin is correlated with disease severity and metabolic syndrome in chronic hepatitis C infection.
Metabolic Syndrome
Serum visfatin levels and metabolic syndrome criteria in obese female subjects.
Metabolic Syndrome
Serum visfatin levels do not increase in post-menopausal women with metabolic syndrome.
Metabolic Syndrome
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Metabolic Syndrome
Study of visfatin expression in acne patients in tissue and serum.
Metabolic Syndrome
The adipokine visfatin is markedly elevated in obese children.
Metabolic Syndrome
The cardiovascular impact of visfatin - an inflammation predictor biomarker in metabolic syndrome.
Metabolic Syndrome
The correlation between insulin-like growth factor 1 (IGF-1) and novel adipocytokines in postmenopausal women: A population-based study.
Metabolic Syndrome
The Impact of Type 2 Diabetes on Circulating Adipokines in Patients with Metabolic Syndrome.
Metabolic Syndrome
The relationship between visfatin and cardiac markers on induced myocardial infarction in rats.
Metabolic Syndrome
The relationship between visfatin and metabolic syndrome in postmenopausal women.
Metabolic Syndrome
The relationship between visfatin and serum concentrations of C-reactive protein, interleukin 6 in patients with metabolic syndrome.
Metabolic Syndrome
The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women.
Metabolic Syndrome
The release of the adipocytokine visfatin is regulated by glucose and insulin.
Metabolic Syndrome
The role of Visfatin in atherosclerotic peripheral arterial obstructive disease.
Metabolic Syndrome
The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis.
Metabolic Syndrome
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Metabolic Syndrome
Visfatin correlates with hot flashes in postmenopausal women with metabolic syndrome: effects of genistein.
Metabolic Syndrome
Visfatin Enhances CXCL8, CXCL10, and CCL20 Production in Human Keratinocytes.
Metabolic Syndrome
Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.
Metabolic Syndrome
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Metabolic Syndrome
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Metabolic Syndrome
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Metabolic Syndrome
Visfatin induces MUC8 and MUC5B expression via p38 MAPK/ROS/NF-?B in human airway epithelial cells.
Metabolic Syndrome
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Metabolic Syndrome
Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Metabolic Syndrome
Visfatin: A Putative Biomarker for Metabolic Syndrome is not Influenced by Pioglitazone or Simvastatin Treatment in Nondiabetic Patients at Cardiovascular Risk - Results from the PIOSTAT Study.
Metabolic Syndrome
Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats.
Metabolic Syndrome
[Inflammatory biomarkers: the link between obesity and associated pathologies]
Migraine Disorders
Plasma Levels of Cyclooxygenase-2 (COX-2) and Visfatin During Different Stages and Different Subtypes of Migraine Headaches.
Mucocutaneous Lymph Node Syndrome
Serum adipokine profiles in Kawasaki disease.
Mucocutaneous Lymph Node Syndrome
[Changes in serum levels of resistin and visfatin in pediatric patients with acute Kawasaki disease following intravenous immune globulin treatment].
Multiple Myeloma
Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity.
Multiple Myeloma
Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.
Multiple Myeloma
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Multiple Myeloma
Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.
Multiple Sclerosis
Obesity in autoimmune diseases: not a passive bystander.
Multiple Sclerosis
Peripheral levels of selected adipokines in patients with newly diagnosed multiple sclerosis.
Muscular Atrophy
Metabolomic and transcriptional profiling reveals bioenergetic stress and activation of cell death and inflammatory pathways in vivo after neuronal deletion of NAMPT.
Myasthenia Gravis
Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients.
Myocardial Infarction
A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
Myocardial Infarction
An elevated plasma level of visfatin increases the risk of myocardial infarction.
Myocardial Infarction
Elevated serum visfatin levels in patients with acute myocardial infarction.
Myocardial Infarction
Increased expression of visfatin in monocytes and macrophages in male acute myocardial infarction patients.
Myocardial Infarction
Inhibition of Nicotinamide Phosphoribosyltransferase Reduces Neutrophil-Mediated Injury in Myocardial Infarction.
Myocardial Infarction
Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction.
Myocardial Infarction
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Myocardial Infarction
NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.
Myocardial Infarction
Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes.
Myocardial Infarction
Plasma levels and leucocyte RNA expression of adipokines in young patients with coronary artery disease, in metabolic syndrome and healthy controls.
Myocardial Infarction
Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction.
Myocardial Infarction
The novel adipocytokine visfatin exerts direct cardioprotective effects.
Myocardial Infarction
The relationship between visfatin and cardiac markers on induced myocardial infarction in rats.
Myocardial Infarction
Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction.
Myocardial Infarction
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Myocardial Ischemia
Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction.
Myocardial Ischemia
Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes.
Myocardial Ischemia
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Myocardial Ischemia
Visfatin and Cardio-Cerebro-Vascular Disease.
Myositis
Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients.
Neonatal Sepsis
Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis.
Neonatal Sepsis
MiR-96-5p alleviates inflammatory responses by targeting NAMPT and regulating the NF-?B pathway in neonatal sepsis.
Neoplasm Metastasis
A Novel Role for the Adipokine Visfatin/Pre-B Cell Colony-enhancing Factor 1 in Prostate Carcinogenesis.
Neoplasm Metastasis
Cohesive cancer invasion of the biophysical barrier of smooth muscle.
Neoplasm Metastasis
Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.
Neoplasm Metastasis
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
Neoplasm Metastasis
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Neoplasm Metastasis
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Neoplasm Metastasis
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Neoplasm Metastasis
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Neoplasm Metastasis
FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.
Neoplasm Metastasis
Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.
Neoplasm Metastasis
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Neoplasm Metastasis
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Neoplasm Metastasis
Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors.
Neoplasm Metastasis
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Neoplasm Metastasis
Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Neoplasm Metastasis
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Neoplasm Metastasis
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Neoplasm Metastasis
Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis.
Neoplasm Metastasis
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis.
Neoplasm Metastasis
Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.
Neoplasm Metastasis
The role of metabolic syndrome variant in the malignant tumors progression.
Neoplasm Metastasis
The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis.
Neoplasm Metastasis
Visfatin increases miR-21 to promote migration in HCC.
Neoplasm Metastasis
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Neoplasm Metastasis
Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2.
Neoplasm Metastasis
Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.
Neoplasm Metastasis
Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway.
Neoplasm Metastasis
Visfatin stimulates proliferation of MCF-7 human breast cancer cells.
Neoplasm Metastasis
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Neoplasms
A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
Neoplasms
A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
Neoplasms
A H2S-Nampt dependent energetic circuit is critical to survival and cytoprotection from damage in cancer cells.
Neoplasms
A new frame in thromboembolic cardiovascular disease: Adipocytokine.
Neoplasms
A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Neoplasms
A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
Neoplasms
A Red-Light-Activated Ruthenium-Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells.
Neoplasms
A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.
Neoplasms
Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.
Neoplasms
Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study.
Neoplasms
Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
Neoplasms
Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
Neoplasms
Adipokines and ?-cell dysfunction in normoglycemic women with previous gestational diabetes mellitus.
Neoplasms
Adipokines and cardiometabolic function: How are they interlinked?
Neoplasms
Adipokines and cytokines in non-alcoholic fatty liver disease.
Neoplasms
Adipokines and Inflammation Alter the Interaction Between Rheumatoid Arthritis Synovial Fibroblasts and Endothelial Cells.
Neoplasms
Adipokines and insulin resistance.
Neoplasms
Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.
Neoplasms
Adipokines demonstrate the interacting influence of central obesity with other cardiometabolic risk factors of metabolic syndrome in Hong Kong Chinese adults.
Neoplasms
Adipokines in gestational diabetes.
Neoplasms
Adipokines: the missing link between insulin resistance and obesity.
Neoplasms
Adiponectin as a biomarker of the metabolic syndrome in children and adolescents.
Neoplasms
Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma.
Neoplasms
Adiponectin: A biomarker for rheumatoid arthritis?
Neoplasms
Adipose Tissue as an Endocrine Organ: An Update on Pro-inflammatory and Anti-inflammatory Microenvironment.
Neoplasms
Adipose Tissue as Regulator of Vascular Tone.
Neoplasms
Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of dIabeteS in obese paTIeNts (The RESISTIN trial).
Neoplasms
Adipose tissue, obesity and adipokines: role in cancer promotion.
Neoplasms
Adipose Tissue: The New Endocrine Organ? A Review Article.
Neoplasms
Advances in NAD-Lowering Agents for Cancer Treatment.
Neoplasms
Aerobic Training Improves Angiogenic Potential Independently of Vascular Endothelial Growth Factor Modifications in Postmenopausal Women.
Neoplasms
Age may determine the effect of hypolipidemic agents on plasma adipokine levels in patients with elevated low-density lipoprotein cholesterol levels.
Neoplasms
An Overview of the Role of Adipokines in Cardiometabolic Diseases.
Neoplasms
An Update on the Emerging Role of Visfatin in the Pathogenesis of Osteoarthritis and Pharmacological Intervention.
Neoplasms
Anti-tumor NAMPT inhibitor, KPT-9274, mediates gender-dependent murine anemia and nephrotoxicity by regulating SIRT3-mediated SOD deacetylation.
Neoplasms
Anticancer agent CHS-828 inhibits cellular synthesis of NAD.
Neoplasms
Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
Neoplasms
Arylurea Derivatives: a Class of Potential Cancer Targeting Agents.
Neoplasms
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Neoplasms
Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients.
Neoplasms
Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Neoplasms
Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway.
Neoplasms
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy.
Neoplasms
Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Neoplasms
Body mass index and adipokines/cytokines dysregulation in systemic sclerosis.
Neoplasms
Boosted photocatalytic activity induced NAMPT-Regulating therapy based on elemental bismuth-humic acids heterojunction for inhibiting tumor proliferation/migration/inflammation.
Neoplasms
Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA.
Neoplasms
Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase.
Neoplasms
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.
Neoplasms
CD73 Protein as a Source of Extracellular Precursors for Sustained NAD+ Biosynthesis in FK866-treated Tumor Cells.
Neoplasms
Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells.
Neoplasms
Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.
Neoplasms
Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Neoplasms
Chemotherapy and plasma adipokines level in patients with colorectal cancer.
Neoplasms
Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk.
Neoplasms
Circulating Serum Level of Visfatin in Patients with Endometrial Cancer.
Neoplasms
Circulating visfatin in chronic obstructive pulmonary disease.
Neoplasms
Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocytokines: A contradictory piece of the puzzle.
Neoplasms
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Neoplasms
Circulating visfatin levels and cancers risk: A systematic review and meta-analysis.
Neoplasms
Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies.
Neoplasms
Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
Neoplasms
Cohesive cancer invasion of the biophysical barrier of smooth muscle.
Neoplasms
Comparative study to evaluate the effect of l-carnitine plus glimepiride versus glimepiride alone on insulin resistance in type 2 diabetic patients.
Neoplasms
Comparison of adipose tissue derived genes in endogenous Cushing's syndrome versus diet-induced obesity.
Neoplasms
Comparison of the effects of short-term hypolipidaemic treatment on plasma adipokine levels in men and women with isolated hypercholesterolaemia.
Neoplasms
Correlation of serum adipocytokine levels with glycolipid metabolism and inflammatory factors in obese patients with periodontal disease.
Neoplasms
Could serum visfatin be a potential biomarker for postmenopausal breast cancer?
Neoplasms
Crystal structure-based comparison of two NAMPT inhibitors.
Neoplasms
Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression.
Neoplasms
Dedifferentiation of cancer cells following recovery from a potentially lethal damage is mediated by H2S-Nampt.
Neoplasms
Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.
Neoplasms
Derivatization of the tricarboxylic acid intermediates with O-benzylhydroxylamine for liquid chromatography-tandem mass spectrometry detection.
Neoplasms
Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents.
Neoplasms
Diet-induced obesity potentiates the growth of gastric cancer in mice.
Neoplasms
Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop.
Neoplasms
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Neoplasms
Dingxin recipe alleviates atherosclerosis injury in ApoE-knockout mice via downregulation of visfatin expression and inhibition of the visfatin-induced inflammatory response.
Neoplasms
Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
Neoplasms
Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer.
Neoplasms
Down-regulation of NAMPT expression by mir-206 reduces cell survival of breast cancer cells.
Neoplasms
Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Neoplasms
DUAL NAMPT AND BTK TARGETING LEADS TO SYNERGISTIC KILLING OF WALDENSTROM`S MACROGLOBULINEMIA CELLS REGARDLESS OF MYD88 AND CXCR4 SOMATIC MUTATIONS STATUS.
Neoplasms
Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer.
Neoplasms
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Neoplasms
Echocardiographic epicardial adipose tissue measurements provide information about cardiovascular risk in hemodialysis patients.
Neoplasms
Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice.
Neoplasms
Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes.
Neoplasms
Effects of small interfering RNA targeting TLR4 on expressions of adipocytokines in obstructive sleep apnea hyponea syndrome with hypertension in a rat model.
Neoplasms
Effects of Systemic Simvastatin on the Concentrations of Visfatin, Tumor Necrosis Factor-?, and Interleukin-6 in Gingival Crevicular Fluid in Patients with Type 2 Diabetes and Chronic Periodontitis.
Neoplasms
Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
Neoplasms
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition.
Neoplasms
Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients.
Neoplasms
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
Neoplasms
Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Neoplasms
Elevated serum visfatin/nicotinamide phosphoribosyl-transferase levels are associated with risk of postmenopausal breast cancer independently from adiponectin, leptin, and anthropometric and metabolic parameters.
Neoplasms
Elevated visfatin levels in obese children are related to proinflammatory factors.
Neoplasms
Emerging Role of Adipocytokines in Type 2 Diabetes as Mediators of Insulin Resistance and Cardiovascular Disease.
Neoplasms
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Neoplasms
Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study.
Neoplasms
Evaluation of diagnostic and predictive value of serum adipokines: Leptin, resistin and visfatin in postmenopausal breast cancer.
Neoplasms
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Neoplasms
Expression of NAMPT is associated with breast invasive ductal carcinoma development and prognosis.
Neoplasms
Expression of nicotinamide phosphoribosyltransferase-influenced genes predicts recurrence-free survival in lung and breast cancers.
Neoplasms
Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
Neoplasms
Extracellular NAMPT/visfatin causes p53 deacetylation via NAD production and SIRT1 activation in breast cancer cells.
Neoplasms
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.
Neoplasms
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine.
Neoplasms
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
Neoplasms
Filifactor alocis and Tumor Necrosis Factor-Alpha Stimulate Synthesis of Visfatin by Human Macrophages.
Neoplasms
FK866 inhibits the epithelial-mesenchymal transition of hepatocarcinoma MHCC97-H cells.
Neoplasms
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Neoplasms
FOXO1 functions in the regulation of nicotinamide phosphoribosyltransferase (Nampt) expression.
Neoplasms
Fragment-based discovery of a potent NAMPT inhibitor.
Neoplasms
Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Neoplasms
From the Cover: Inhibitors of Nicotinamide Phosphoribosyltransferase Cause Retinal Damage in Larval Zebrafish.
Neoplasms
Genetic predisposition to acute kidney injury induced by severe sepsis.
Neoplasms
Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.
Neoplasms
Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Neoplasms
Handgrip strength, tumor necrosis factor-?, interlukin-6, and visfatin levels in oldest elderly patients with cognitive impairment.
Neoplasms
HDAC Inhibitor Sodium Butyrate Augments the MEF2C Enhancement of Nampt Expression under Hypoxia.
Neoplasms
High Leptin/Adiponectin Ratio and Serum Triglycerides Are Associated With an "At-Risk" Phenotype in Young Severely Obese Patients.
Neoplasms
High level of visfatin and the activation of Akt and ERK1/2 signaling pathways are associated with endometrium malignant transformation in polycystic ovary syndrome.
Neoplasms
High Visfatin Expression in Breast Cancer Tissue Is Associated with Poor Survival.
Neoplasms
High visfatin expression predicts poor prognosis of upper tract urothelial carcinoma patients.
Neoplasms
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Neoplasms
Hypothalamic ischemia and metabolic syndrome Comment to: Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Jerzy BeÅtowski Med Sci Monit, 2006; 12(6): RA112-19.
Neoplasms
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
Neoplasms
Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
Neoplasms
Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD(+) biosynthesis pathway and NAMPT mutation.
Neoplasms
Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.
Neoplasms
Identification of the Nicotinamide Salvage Pathway as a New Toxification Route for Antimetabolites.
Neoplasms
Impact of 14-day bed rest on serum adipokines and low-grade inflammation in younger and older adults.
Neoplasms
Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative.
Neoplasms
Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.
Neoplasms
Increased levels and adipose tissue expression of visfatin in morbidly obese women. The relationship with pro-inflammatory cytokines.
Neoplasms
Increased Nicotinamide Phosphoribosyltransferase and Cystathionine-?-Synthase in Renal Oncocytomas, Renal Urothelial Carcinoma, and Renal Clear Cell Carcinoma.
Neoplasms
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Neoplasms
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Neoplasms
Increased serum leptin levels are associated with metabolic syndrome and carotid intima media thickness in premenopausal systemic lupus erythematosus patients without clinical atherosclerotic vascular events.
Neoplasms
Increased Serum Levels of Tumor Necrosis Factor-Alpha, Resistin, and Visfatin in the Children with Autism Spectrum Disorders: A Case-Control Study.
Neoplasms
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Neoplasms
Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes.
Neoplasms
Inflammation and fatness in adolescents with and without Down syndrome: UP & DOWN study.
Neoplasms
Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
Neoplasms
Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Neoplasms
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer.
Neoplasms
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma.
Neoplasms
Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Neoplasms
Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
Neoplasms
Inhibition of Nicotinamide Phosphoribosyltransferase Induces Apoptosis in Estrogen Receptor-Positive MCF-7 Breast Cancer Cells.
Neoplasms
Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
Neoplasms
Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool.
Neoplasms
Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Neoplasms
Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans.
Neoplasms
Intracellular Nampt impairs esophageal squamous cell carcinoma neo-adjuvant chemotherapy response independent of eNampt.
Neoplasms
Intrauterine growth restriction and adult disease: the role of adipocytokines.
Neoplasms
Investigating the effect of visfatin on ERalpha phosphorylation (Ser118 and Ser167) and ERE-dependent transcriptional activity.
Neoplasms
Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.
Neoplasms
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells.
Neoplasms
Involvement of visfatin in palmitate-induced upregulation of inflammatory cytokines in hepatocytes.
Neoplasms
Is peritoneal dialysis causing a measurable burden of inflammatory and endothelial injury on top of metabolic syndrome?
Neoplasms
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Neoplasms
Laparoscopic sleeve gastrectomy induces molecular changes in peripheral white blood cells.
Neoplasms
Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease.
Neoplasms
Lipases and lipid droplet-associated protein expression in subcutaneous white adipose tissue of cachectic patients with cancer.
Neoplasms
Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
Neoplasms
Maternal leptin, adiponectin, resistin, visfatin and tumor necrosis factor-alpha in normal and gestational diabetes.
Neoplasms
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma.
Neoplasms
Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors.
Neoplasms
Melatonin reduces obesity and restores adipokine patterns and metabolism in obese (ob/ob) mice.
Neoplasms
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Neoplasms
Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.
Neoplasms
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.
Neoplasms
Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.
Neoplasms
Metabolomics analysis of metabolic effects of nicotinamide phosphoribosyltransferase (NAMPT) inhibition on human cancer cells.
Neoplasms
MicroRNA Mediate Visfatin and Resistin Induction of Oxidative Stress in Human Osteoarthritic Synovial Fibroblasts Via NF-?B Pathway.
Neoplasms
MicroRNA-494 induces breast cancer cell apoptosis and reduces cell viability by inhibition of nicotinamide phosphoribosyltransferase expression and activity.
Neoplasms
Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
Neoplasms
Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression.
Neoplasms
Modulation of cardiovascular function by adipokines.
Neoplasms
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents.
Neoplasms
Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin.
Neoplasms
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma.
Neoplasms
NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.
Neoplasms
NAD Metabolism in Cancer Therapeutics.
Neoplasms
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
Neoplasms
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.
Neoplasms
NAD+ metabolism controls growth inhibition by HIF1 in normoxia and determines differential sensitivity of normal and cancer cells.
Neoplasms
NAD+ metabolism controls inflammation during senescence.
Neoplasms
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.
Neoplasms
NAD+ metabolism, stemness, the immune response, and cancer.
Neoplasms
NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
Neoplasms
NAMPT and NAPRT1: novel polymorphisms and distribution of variants between normal tissues and tumor samples.
Neoplasms
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
Neoplasms
NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance.
Neoplasms
NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism.
Neoplasms
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by ?-lapachone.
Neoplasms
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Neoplasms
NAMPT inhibition synergizes with NQO1-targeting agents in inducing apoptotic cell death in non-small cell lung cancer cells.
Neoplasms
Nampt is involved in DNA double-strand break repair.
Neoplasms
NAMPT is the cellular target of STF-31-like small-molecule probes.
Neoplasms
NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma.
Neoplasms
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.
Neoplasms
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.
Neoplasms
NAMPT regulates PKM2 nuclear location through 14-3-3?: Conferring resistance to tamoxifen in breast cancer.
Neoplasms
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Neoplasms
NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils.
Neoplasms
NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
Neoplasms
NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Neoplasms
Nampt/PBEF/visfatin and cancer.
Neoplasms
Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1?, and anemia.
Neoplasms
Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors.
Neoplasms
NAMPT: A potential prognostic and therapeutic biomarker in patients with glioblastoma.
Neoplasms
Nampt: linking NAD biology, metabolism and cancer.
Neoplasms
New concepts in white adipose tissue physiology.
Neoplasms
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology.
Neoplasms
Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target.
Neoplasms
Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.
Neoplasms
Nicotinamide phosphoribosyl transferase (Nampt) is a target of microRNA-26b in colorectal cancer cells.
Neoplasms
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.
Neoplasms
Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
Neoplasms
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Neoplasms
Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
Neoplasms
Nicotinamide Phosphoribosyltransferase (NAMPT) acts as a metabolic gate for mobilization of myeloid-derived suppressor cells.
Neoplasms
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities.
Neoplasms
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience.
Neoplasms
Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is a tumoural cytokine released from melanoma.
Neoplasms
Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages.
Neoplasms
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Neoplasms
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Neoplasms
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders.
Neoplasms
Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
Neoplasms
Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma.
Neoplasms
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Neoplasms
Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
Neoplasms
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.
Neoplasms
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Neoplasms
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Neoplasms
Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Neoplasms
Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation.
Neoplasms
Nuclear transport of nicotinamide phosphoribosyltransferase is cell cycle-dependent in mammalian cells, and its inhibition slows cell growth.
Neoplasms
Obesity in chronic kidney disease: good or bad?
Neoplasms
Obesity Potentiates Esophageal Squamous Cell Carcinoma Growth and Invasion by AMPK-YAP Pathway.
Neoplasms
Optimization and bioactivity verification of porcine recombinant visfatin with high expression and low endotoxin content using pig liver as template.
Neoplasms
Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.
Neoplasms
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Neoplasms
PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?
Neoplasms
Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Neoplasms
Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents.
Neoplasms
Physical activity and adipokine levels in individuals with type 2 diabetes: A literature review and practical applications.
Neoplasms
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Neoplasms
Physiological, pathological and potential therapeutic roles of adipokines.
Neoplasms
Plasma and myocardial visfatin expression changes are associated with therapeutic hypothermia protection during murine hemorrhagic shock/resuscitation.
Neoplasms
Plasma visfatin and tumor necrosis factor-alpha (TNF-a) levels in metabolic syndrome.
Neoplasms
Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Neoplasms
Pre-B-cell colony-enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium.
Neoplasms
Preclinical Assessment of the ADME, Efficacy and Drug-Drug Interaction Potential of a Novel NAMPT Inhibitor.
Neoplasms
Preclinical models of nicotinamide phosphoribosyltransferase inhibitor-mediated hematotoxicity and mitigation by co-treatment with nicotinic acid.
Neoplasms
Preoperative serum visfatin levels and prognosis of breast cancer among Chinese women.
Neoplasms
Prognostic value of visfatin in various human malignancies: A systematic review and meta-analysis.
Neoplasms
Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy.
Neoplasms
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.
Neoplasms
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Neoplasms
Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer.
Neoplasms
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Neoplasms
Resistin, visfatin, adiponectin, and leptin: risk of breast cancer in pre- and postmenopausal saudi females and their possible diagnostic and predictive implications as novel biomarkers.
Neoplasms
Reviews: adipocytokines in normal and complicated pregnancies.
Neoplasms
Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease.
Neoplasms
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
Neoplasms
Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach.
Neoplasms
Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target.
Neoplasms
Role of visfatin in promoting proliferation and invasion of colorectal cancer cells by downregulating SDF-1/CXCR4-mediated miR-140-3p expression.
Neoplasms
Roles and mechanisms of adipokines in drug resistance of tumor cells.
Neoplasms
Screening common signaling pathways associated with drug resistance in non-small cell lung cancer via gene expression profile analysis.
Neoplasms
Secretion of one adipokine Nampt/Visfatin suppresses the inflammatory stress-induced NF-?B activity and affects Nampt-dependent cell viability in Huh-7 cells.
Neoplasms
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Neoplasms
Serum adipokine concentrations in dogs with diabetes mellitus: a pilot study.
Neoplasms
Serum amyloid A - A prime candidate for identification of neonatal sepsis.
Neoplasms
Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease.
Neoplasms
Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
Neoplasms
Serum level of visfatin can reflect the severity of inflammation in patients with acute cholecystitis.
Neoplasms
Serum levels of selected adipocytokines in benign and malignant parotid gland tumor patients.
Neoplasms
Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC).
Neoplasms
Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism.
Neoplasms
Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-?) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
Neoplasms
Significance of Some Non-Invasive Biomarkers in the Early Diagnosis and Staging of Egyptian Breast Cancer Patients.
Neoplasms
SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells.
Neoplasms
Sleep duration, cardiovascular disease, and proinflammatory biomarkers.
Neoplasms
Small interfering RNA-mediated silencing of nicotinamide phosphoribosyltransferase (NAMPT) and lysosomal trafficking regulator (LYST) induce growth inhibition and apoptosis in human multiple myeloma cells: A preliminary study.
Neoplasms
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Neoplasms
Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
Neoplasms
Structural basis for resistance to diverse classes of NAMPT inhibitors.
Neoplasms
Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors.
Neoplasms
Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Neoplasms
Structure-based virtual screening, molecular dynamics simulation and in vitro evaluation to identify inhibitors against NAMPT.
Neoplasms
Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
Neoplasms
Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction.
Neoplasms
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Neoplasms
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Neoplasms
Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
Neoplasms
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Neoplasms
Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation.
Neoplasms
Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
Neoplasms
Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.
Neoplasms
The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo.
Neoplasms
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD(+) Depletion-Mediated Cytotoxicity.
Neoplasms
The association between clinically suspect arthralgia and adipokines in obese patients.
Neoplasms
The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes.
Neoplasms
The Correlation of Visfatin and Its Gene Polymorphism with Non-Small Cell Lung Cancer.
Neoplasms
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5).
Neoplasms
The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer.
Neoplasms
The Effect of Onion Peel Extract on Inflammatory Mediators in Korean Overweight and Obese Women.
Neoplasms
The effect of short-term combined treatment with simvastatin and ezetimibe on circulating adipokine levels in patients with isolated hypercholesterolemia.
Neoplasms
The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report.
Neoplasms
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
Neoplasms
The effects of aerobic, resistance, and combined exercise on metabolic control, inflammatory markers, adipocytokines, and muscle insulin signaling in patients with type 2 diabetes mellitus.
Neoplasms
The effects of fat distribution and some adipokines on insulin resistance.
Neoplasms
The effects of physical activity on adipokines in individuals with overweight/obesity across the lifespan: A narrative review.
Neoplasms
The Impact of CDH13 Polymorphism and Statin Administration on TG/HDL Ratio in Cardiovascular Patients.
Neoplasms
The metabolic syndrome and adipocytokines.
Neoplasms
The NAD(+) salvage pathway modulates cancer cell viability via p73.
Neoplasms
The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis.
Neoplasms
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Neoplasms
The NAMPT/E2F2/SIRT1 axis promotes proliferation and inhibits p53-dependent apoptosis in human melanoma cells.
Neoplasms
The nicotinamide phosphoribosyltransferase antagonist FK866 inhibits growth of prostate tumour spheroids and increases doxorubicin retention without changes in drug transporter and cancer stem cell protein expression.
Neoplasms
The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer.
Neoplasms
The potential of adipokines as biomarkers and therapeutic agents for vascular complications in type 2 diabetes mellitus.
Neoplasms
The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome.
Neoplasms
The role of cholinergic anti-inflammatory pathway in acetic acid-induced colonic inflammation in the rat.
Neoplasms
The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.
Neoplasms
The role of extracellular and intracellular nicotinamide phosphoribosyl-transferase in cancer: diagnostic and therapeutic perspectives and challenges.
Neoplasms
The role of metabolic syndrome variant in the malignant tumors progression.
Neoplasms
The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis.
Neoplasms
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Neoplasms
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.
Neoplasms
Treatment of Cancer with NAMPT Inhibitors.
Neoplasms
Tumor Metabolic Reprogramming by Adipokines as a Critical Driver of Obesity-Associated Cancer Progression.
Neoplasms
Tumor necrosis factor-? enhances hyperbaric oxygen-induced visfatin expression via JNK pathway in human coronary arterial endothelial cells.
Neoplasms
Unravelling the Role of LncRNA WT1-AS/miR-206/NAMPT Axis as Prognostic Biomarkers in Lung Adenocarcinoma.
Neoplasms
Up-regulation of miR-381 inhibits NAD+ salvage pathway and promotes apoptosis in breast cancer cells.
Neoplasms
Upregulation of the adipokine genes ADIPOR1 and SPP1 is related to poor survival outcomes in colorectal cancer.
Neoplasms
Utilization of 18F-Fluorodeoxyglucose-Positron Emission Tomography To Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors In Vivo.
Neoplasms
Visfatin and endothelial function in dialyzed patients.
Neoplasms
Visfatin and global histone H3K9me levels in colon cancer.
Neoplasms
Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization.
Neoplasms
Visfatin effects on telomerase gene expression in AGS gastric cancer cell line.
Neoplasms
Visfatin Enhances the Production of Cathelicidin Antimicrobial Peptide, Human ?-Defensin-2, Human ?-Defensin-3, and S100A7 in Human Keratinocytes and Their Orthologs in Murine Imiquimod-Induced Psoriatic Skin.
Neoplasms
Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway.
Neoplasms
Visfatin expression in subcutaneous adipose tissue of pre-menopausal women: relation to hormones and weight reduction.
Neoplasms
Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.
Neoplasms
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Neoplasms
Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF-?B signaling.
Neoplasms
Visfatin in gestational diabetes: serum level and mRNA expression in fat and placental tissue.
Neoplasms
Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway.
Neoplasms
Visfatin induces sickness responses in the brain.
Neoplasms
Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia.
Neoplasms
Visfatin is expressed in human granulosa cells: regulation by metformin through AMPK/SIRT1 pathways and its role in steroidogenesis.
Neoplasms
Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism.
Neoplasms
Visfatin Levels in Behcet's Disease.
Neoplasms
Visfatin Mediates Malignant Behaviors through Adipose-Derived Stem Cells Intermediary in Breast Cancer.
Neoplasms
Visfatin Mediates SCLC Cells Migration across Brain Endothelial Cells through Upregulation of CCL2.
Neoplasms
Visfatin promotes cell and tumor growth by upregulating Notch1 in breast cancer.
Neoplasms
Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.
Neoplasms
Visfatin promotes the malignancy of human acute myeloid leukemia cells via regulation of IL-17.
Neoplasms
Visfatin Promotes the Metastatic Potential of Chondrosarcoma Cells by Stimulating AP-1-Dependent MMP-2 Production in the MAPK Pathway.
Neoplasms
Visfatin regulates the production of lipopolysaccharide-induced inflammatory cytokines through p38 signaling in murine macrophages.
Neoplasms
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Neoplasms
Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
Neoplasms
Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-?B/IL-6 signals.
Neoplasms
Visfatin, a potential biomarker and prognostic factor for endometrial cancer.
Neoplasms
[Adipocytokines as mediators of metabolic role of adipose tissue].
Neoplasms
[Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis]
Neoplasms
[Adipose tissue as an endocrine organ].
Neoplasms
[Effects of FK866 on migration of A549 cells and related mechanism].
Neoplasms
[EXPRESSION OF PFKFB, HK2, NAMPT, TSPAN13 AND HSPB8 GENES IN PEDIATRIC GLIOMA].
Neoplasms
[FK866 protects polymicrobial sepsis-induced liver injury in mice].
Neoplasms
[Inflammatory biomarkers: the link between obesity and associated pathologies]
Neoplasms
[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].
Neoplasms
[SECRETORY FUNCTION OF WHITE ADIPOSE TISSUE AND ADIPOKINES: BIOLOGICAL EFFECTS AND CLINICAL SIGNIFICANCE (REVIEW)].
Neoplasms
[The research advances in the relationship between visfatin and cancer].
Neoplasms
[The role of the fat tissue and its hormones in the mechanisms of insulin resistance and the development of type 2 diabetes mellitus]
Neoplasms, Squamous Cell
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Neuralgia
Does Serum Visfatin Represent a Biochemical Marker to an Experimental Peripheral Neuropathic Pain in Mice.
Neuroblastoma
Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells.
Neurodegenerative Diseases
Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease.
Neurodegenerative Diseases
Nicotinamide phosphoribosyltransferase inhibitor ameliorates mouse aging-induced cognitive impairment.
Neurodegenerative Diseases
Nicotinamide phosphoribosyltransferase?related signaling pathway in early Alzheimer's disease mouse models.
Neurodegenerative Diseases
Targeting Nicotinamide Phosphoribosyltransferase as a Potential Therapeutic Strategy to Restore Adult Neurogenesis.
Neuroectodermal Tumors, Primitive
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.
Neuroectodermal Tumors, Primitive
PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Neuroendocrine Tumors
Extracellular Nampt (eNampt/Visfatin/PBEF) directly and indirectly stimulates ACTH and CCL2 protein secretion from isolated rat corticotropes.
Neuroendocrine Tumors
NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
Neuroinflammatory Diseases
Metabolomic and transcriptional profiling reveals bioenergetic stress and activation of cell death and inflammatory pathways in vivo after neuronal deletion of NAMPT.
Neuroinflammatory Diseases
NAMPT and BMAL1 Are Independently Involved in the Palmitate-Mediated Induction of Neuroinflammation in Hypothalamic Neurons.
Neuroinflammatory Diseases
NAMPT inhibitor protects ischemic neuronal injury in rat brain via anti-neuroinflammation.
Neuroinflammatory Diseases
Nicotinamide phosphoribosyltransferase secreted from microglia via exosome during ischemic injury.
Neutropenia
GM-CSF treatment is not effective in congenital neutropenia patients due to its inability to activate NAMPT signaling.
Neutropenia
NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.
nicotinamide phosphoribosyltransferase deficiency
Adipose tissue NAD+ biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice.
nicotinamide phosphoribosyltransferase deficiency
Nicotinamide phosphoribosyltransferase (Nampt) affects the lineage fate determination of mesenchymal stem cells: a possible cause for reduced osteogenesis and increased adipogenesis in older individuals.
nicotinamide phosphoribosyltransferase deficiency
Nicotinamide phosphoribosyltransferase (Nampt) may serve as the marker for osteoblast differentiation of bone marrow-derived mesenchymal stem cells.
nicotinamide phosphoribosyltransferase deficiency
Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP.
nicotinamide phosphoribosyltransferase deficiency
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Non-alcoholic Fatty Liver Disease
A composite model including visfatin, tissue polypeptide-specific antigen, hyaluronic acid, and hematological variables for the diagnosis of moderate-to-severe fibrosis in nonalcoholic fatty liver disease: a preliminary study.
Non-alcoholic Fatty Liver Disease
Adipokines and cytokines in non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Adipokines in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Association Between Visfatin and Hepatic Steatosis in the General Population During Long-Term Follow-Up.
Non-alcoholic Fatty Liver Disease
Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Association of Circulating Adipsin, Visfatin, and Adiponectin with Nonalcoholic Fatty Liver Disease in Adults: A Case-Control Study.
Non-alcoholic Fatty Liver Disease
Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Effect of curcumin on visfatin and zinc-?2-glycoprotein in a rat model of non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Hepatic NAD salvage pathway is enhanced in mice on a high-fat diet.
Non-alcoholic Fatty Liver Disease
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery.
Non-alcoholic Fatty Liver Disease
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Non-alcoholic Fatty Liver Disease
Nicotinamide Phosphoribosyltransferase Knockdown Leads to Lipid Accumulation in HepG2 Cells through The SIRT1-AMPK Pathway.
Non-alcoholic Fatty Liver Disease
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Non-alcoholic Fatty Liver Disease
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Non-alcoholic Fatty Liver Disease
Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
Non-alcoholic Fatty Liver Disease
Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease.
Non-alcoholic Fatty Liver Disease
Serum visfatin in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Non-alcoholic Fatty Liver Disease
Serum Visfatin Levels in Nonalcoholic Fatty Liver Disease and Liver Fibrosis: Systematic Review and Meta-Analysis.
Non-alcoholic Fatty Liver Disease
Visceral adipose tissue visfatin in nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Non-alcoholic Fatty Liver Disease
Visfatin and TGF-?1 in primary biliary cirrhosis and two other common liver diseases.
Non-alcoholic Fatty Liver Disease
Visfatin exacerbates hepatic inflammation and fibrosis in a methionine-choline-deficient diet mouse model.
Non-alcoholic Fatty Liver Disease
Visfatin Induces Inflammation and Insulin Resistance via the NF-?B and STAT3 Signaling Pathways in Hepatocytes.
Non-alcoholic Fatty Liver Disease
Visfatin levels in nonalcoholic Fatty liver disease.
Non-alcoholic Fatty Liver Disease
[Evaluation of serum visfatin concentrations in children with nonalcoholic fatty liver disease]
Non-alcoholic Fatty Liver Disease
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Non-alcoholic Fatty Liver Disease
[The role of adipokines and insulin resistance in the pathogenesis of nonalcoholic fatty liver disease]
Non-Radiographic Axial Spondyloarthritis
Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.
Obesity
A Common Haplotype in NAPEPLD Is Associated With Severe Obesity in a Norwegian Population-Based Cohort (the HUNT Study).
Obesity
A novel adipocytokine visfatin protects against H(2)O(2) -induced myocardial apoptosis: a missing link between obesity and cardiovascular disease.
Obesity
A novel single-nucleotide polymorphism of the visfatin gene and its associations with performance traits in the chicken.
Obesity
A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity.
Obesity
A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis.
Obesity
ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity.
Obesity
Acute and Chronic Effects of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Visfatin and Apelin Levels in Patients with Severe Obesity.
Obesity
Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
Obesity
Adipokine Visfatin's Role in Pathogenesis of Diabesity and Related Metabolic Derangements.
Obesity
Adipokines and etiopathology of metabolic disorders.
Obesity
Adipokines Vaspin and Visfatin in Obese Children.
Obesity
Adiponectin Signaling and Impaired GTPase Rab5 Expression in Adipocytes of Adolescents with Obesity.
Obesity
Adiponectin, Leptin and Visfatin in Hypoxia and its Effect for Weight Loss in Obesity.
Obesity
Adipose tissue, obesity and adipokines: role in cancer promotion.
Obesity
An evaluation of visfatin levels in obese subjects.
Obesity
An Overview of the Role of Adipokines in Cardiometabolic Diseases.
Obesity
An update on visfatin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity.
Obesity
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Obesity
Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.
Obesity
Association of adipokines with obesity in children and adolescents.
Obesity
Association of genetic variability in selected regions in visfatin (NAMPT) gene with anthropometric parameters and dietary composition in obese and non-obese Central-European population.
Obesity
Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity.
Obesity
Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes in humans.
Obesity
Associations between Adipokines in Arthritic Disease and Implications for Obesity.
Obesity
Autoantibody Production in Obesity: Is There Evidence for a Link Between Obesity and Autoimmunity?
Obesity
Body fat distribution has no effect on serum visfatin levels in healthy female subjects.
Obesity
Body mass index and adipokines/cytokines dysregulation in systemic sclerosis.
Obesity
Can adipokine visfatin be a novel marker of pregnancy-related disorders in women with obesity?
Obesity
Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.
Obesity
Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice.
Obesity
Circulating adipokines and mRNA expression in adipose tissue and the placenta in women with gestational diabetes mellitus.
Obesity
Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA).
Obesity
Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Obesity
Common variants in LEPR, IL6, AMD1, and NAMPT do not associate with risk of juvenile and childhood obesity in Danes: a case-control study.
Obesity
Comparing the prolonged effect of interval versus continuous aerobic exercise on blood inflammatory marker of Visfatin level and body mass index of sedentary overweigh/fat female college students.
Obesity
Curcumin down-regulates visfatin expression and inhibits breast cancer cell invasion.
Obesity
Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop.
Obesity
Dietary and physical activity patterns in children with obstructive sleep apnea.
Obesity
Dietary Antioxidant Trans-Cinnamaldehyde Reduced Visfatin-Induced Breast Cancer Progression: In Vivo and In Vitro Study.
Obesity
Differential Expression of Human N-Alpha-Acetyltransferase 40 (hNAA40), Nicotinamide Phosphoribosyltransferase (NAMPT) and Sirtuin-1 (SIRT-1) Pathway in Obesity and T2DM: Modulation by Metformin and Macronutrient Intake.
Obesity
Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism.
Obesity
Do novel adipokines play a causative or only modulating role in the pathogenesis of obesity and metabolic disorders?
Obesity
Effect of exercise training on plasma visfatin and eotaxin levels.
Obesity
Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
Obesity
Effect of simvastatin treatment on plasma visfatin levels in obese women.
Obesity
Effects of 12 weeks of combined exercise training on visfatin and metabolic syndrome factors in obese middle-aged women.
Obesity
Effects of Diet-Induced Obesity on Tracheal Responsiveness to Methacholine, Tracheal Visfatin Level, and Lung Histological Changes in Ovalbumin-Sensitized Female Wistar Rats.
Obesity
Effects of fatty acid regulation on visfatin gene expression in adipocytes.
Obesity
Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children.
Obesity
Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.
Obesity
Effects of visfatin on brown adipose tissue energy regulation using T37i cells.
Obesity
Elevated 1-hour post-load plasma glucose identifies obese youth with abnormal glucose metabolism and an unfavorable inflammatory profile.
Obesity
Elevated microRNA-34a in obesity reduces NAD(+) levels and SIRT1 activity by directly targeting NAMPT.
Obesity
Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
Obesity
Elevated vaspin and leptin levels are associated with obesity in prepubertal Korean children.
Obesity
Elevated visfatin levels in obese children are related to proinflammatory factors.
Obesity
Endothelial NLRP3 Inflammasome Activation and Enhanced Neointima Formation in Mice by Adipokine Visfatin.
Obesity
Ethnic-specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function.
Obesity
Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
Obesity
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Obesity
Experimental obesity and diabetes reduce male fertility: Potential involvement of hypothalamic Kiss-1, pituitary nitric oxide, serum vaspin and visfatin.
Obesity
Exploring the Crosstalk between Hydrostatic Pressure and Adipokines: An In Vitro Study on Human Osteoarthritic Chondrocytes.
Obesity
Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism.
Obesity
Fasting- and ghrelin-induced food intake is regulated by NAMPT in the hypothalamus.
Obesity
Functional effects of visfatin in isolated rat mesenteric small resistance arteries.
Obesity
Genetic associations of the visfatin G-948T polymorphism with obesity-related metabolic traits in an Iranian population.
Obesity
Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population.
Obesity
Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans.
Obesity
Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.
Obesity
Impact of metabolic regulators on the expression of the obesity associated genes FTO and NAMPT in human preadipocytes and adipocytes.
Obesity
Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats.
Obesity
In Vivo and Ex Vivo Regulation of Visfatin Production by Leptin in Human and Murine Adipose Tissue: Role of MAPK and PI3-K Signalling Pathways.
Obesity
Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.
Obesity
Increased Visfatin Expression Is Associated with Nuclear Factor-?B in Obese Ovalbumin-Sensitized Male Wistar Rat Tracheae.
Obesity
Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin.
Obesity
Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose.
Obesity
Instigation of endothelial Nlrp3 inflammasome by adipokine visfatin promotes inter-endothelial junction disruption: role of HMGB1.
Obesity
Insulin-like effects of visfatin on human osteoblasts.
Obesity
Interactions between adiponectin, visfatin, and omentin in subcutaneous and visceral adipose tissues and serum, and correlations with clinical and peripheral metabolic factors.
Obesity
Investigating the effect of visfatin on ERalpha phosphorylation (Ser118 and Ser167) and ERE-dependent transcriptional activity.
Obesity
Involvement of Novel Adipokines, Chemerin, Visfatin, Resistin and Apelin in Reproductive Functions in Normal and Pathological Conditions in Humans and Animal Models.
Obesity
Lack of effect of a moderate hypocaloric diet on visfatin levels in morbid obese patients: relationship with insulin resistance.
Obesity
Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans.
Obesity
Lipotoxicity versus adipotoxicity-The deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes.
Obesity
Liver X Receptor (LXR) activation negatively regulates visfatin expression in macrophages.
Obesity
Lower plasma NAMPT/visfatin levels are associated with impaired hepatic mitochondrial function in non-diabetic obese women: a potential link between obesity and non-alcoholic fatty liver disease.
Obesity
Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin.
Obesity
Maternal visfatin concentration in normal pregnancy.
Obesity
MC4R Variant rs17782313 Associates With Increased Levels of DNAJC27, Ghrelin, and Visfatin and Correlates With Obesity and Hypertension in a Kuwaiti Cohort.
Obesity
Measurement of novel adipokine visfatin in young patients with acute myocardial infarction. Clinical testing of a new ELISA.
Obesity
Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin.
Obesity
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Obesity
Molecular characteristics of serum visfatin and differential detection by immunoassays.
Obesity
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
Obesity
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Obesity
NAMPT-mediated NAD
Obesity
Nicotinamide phosphoribosyl-transferase/visfatin: A missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges.
Obesity
Nicotinamide Phosphoribosyltransferase (Nampt)/Nicotinamide Adenine Dinucleotide (NAD) Axis Suppresses Atrial Fibrillation by Modulating the Calcium Handling Pathway.
Obesity
Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation.
Obesity
Obesity and Cardiovascular Risk: Variations in Visfatin Gene Can Modify the Obesity Associated Cardiovascular Risk. Results from the Segovia Population Based-Study. Spain.
Obesity
Obesity and obstructive sleep apnea syndrome.
Obesity
Obesity in autoimmune diseases: not a passive bystander.
Obesity
Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome.
Obesity
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Obesity
Plasma concentration and expression of adipokines in epicardial and subcutaneous adipose tissue are associated with impaired left ventricular filling pattern.
Obesity
Plasma visfatin and retinol binding protein-4 levels in patients with type 2 diabetes mellitus and their relationship to adiposity and fatty liver.
Obesity
Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.
Obesity
Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass.
Obesity
Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.
Obesity
Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Obesity
Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Obesity
Plasma visfatin levels in severe obstructive sleep apnea-hypopnea syndrome.
Obesity
Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome.
Obesity
Potential role of peroxisome proliferator activated receptor gamma activation on serum visfatin and trace elements in high fat diet induced type 2 diabetes mellitus.
Obesity
Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
Obesity
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin.
Obesity
Regulation of adipokine secretion by n-3 fatty acids.
Obesity
Regulation of regenerative periodontal healing by NAMPT.
Obesity
Regulation of visfatin by microbial and biomechanical signals in PDL cells.
Obesity
Relationship between cerebrospinal fluid visfatin (PBEF/Nampt) levels and adiposity in humans.
Obesity
Relationship between serum visfatin levels and coronary slow-flow phenomenon.
Obesity
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity.
Obesity
Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
Obesity
Risk analysis of systemic levels of estrogen and adipokines as well as estrogen receptors from PBMCs in childbearing and perimenopausal women with obesity.
Obesity
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
Obesity
Role of obesity-associated dysfunctional adipose tissue in cancer: A molecular nutrition approach.
Obesity
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus.
Obesity
Serum concentration of visfatin in obese women.
Obesity
Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity.
Obesity
Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome.
Obesity
Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
Obesity
Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism.
Obesity
Serum visfatin concentration and its relationship with sex hormones in obese Saudi women.
Obesity
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Obesity
Serum Visfatin does not seem to be a Useful Marker to Guide Glucocorticoid Substitution in Adrenal Insufficiency.
Obesity
Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Obesity
Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity.
Obesity
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Obesity
Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter.
Obesity
Serum visfatin levels and metabolic syndrome criteria in obese female subjects.
Obesity
Serum visfatin levels in a group of Egyptian obese individuals.
Obesity
Serum visfatin levels in patients with anorexia nervosa and bulimia nervosa.
Obesity
Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-?) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
Obesity
Sleep Deficiency is a Modifiable Risk Factor for Obesity and Cognitive Impairment and Associated with Elevated Visfatin.
Obesity
Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells.
Obesity
Strong association of the polymorphisms in PBEF1 and knee OA risk: a two-stage population-based study in China.
Obesity
The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion.
Obesity
The association between clinically suspect arthralgia and adipokines in obese patients.
Obesity
The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
Obesity
The FTO Obesity Gene. Genotyping and Gene Expression Analysis in Morbidly Obese Patients.
Obesity
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
Obesity
The relationship between visfatin and cardiac markers on induced myocardial infarction in rats.
Obesity
The role of adipokines in periodontal infection and healing.
Obesity
The role of Visfatin and Resistin in an In Vitro Model of Obesity-Induced Invasive Liver Cancer.
Obesity
The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis.
Obesity
The role of visfatin in diabetic nephropathy.
Obesity
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Obesity
The up-regulation of markers of adipose tissue fibrosis by visfatin in pre-adipocytes as well as obese children and adolescents.
Obesity
The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects.
Obesity
TNF-alpha alters visfatin and adiponectin levels in human fat.
Obesity
Tumor Metabolic Reprogramming by Adipokines as a Critical Driver of Obesity-Associated Cancer Progression.
Obesity
Visfatin and adiponectin levels in children: relationships with physical activity and metabolic parameters.
Obesity
Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children.
Obesity
Visfatin and its role in obesity development.
Obesity
Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome.
Obesity
Visfatin and SREBP-1c mRNA Expressions and Serum Levels Among Egyptian Women with Polycystic Ovary Syndrome.
Obesity
Visfatin as a therapeutic target for rheumatoid arthritis.
Obesity
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Obesity
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Obesity
Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes.
Obesity
Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Obesity
Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity.
Obesity
Visfatin in adipocytes is upregulated by hypoxia through HIF1alpha-dependent mechanism.
Obesity
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Obesity
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Obesity
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome, and cardiovascular diseases: A meta-analysis and systemic review.
Obesity
Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis.
Obesity
Visfatin induces MUC8 and MUC5B expression via p38 MAPK/ROS/NF-?B in human airway epithelial cells.
Obesity
Visfatin induces sickness responses in the brain.
Obesity
Visfatin is associated with lipid metabolic abnormalities in Lyon hypertensive rats.
Obesity
Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy.
Obesity
Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NF?B and JNK in human abdominal subcutaneous adipocytes.
Obesity
Visfatin levels in prepubertal children born small or large for gestational age.
Obesity
Visfatin Promotes Monocyte Adhesion by Upregulating ICAM-1 and VCAM-1 Expression in Endothelial Cells via Activation of p38-PI3K-Akt Signaling and Subsequent ROS Production and IKK/NF-?B Activation.
Obesity
Visfatin Serum Levels in Obese Type 2 Diabetic Patients: Relation to Proinflammatory Cytokines and Insulin Resistance.
Obesity
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Obesity
Visfatin Triggers Anorexia and Body Weight Loss through Regulating the Inflammatory Response in the Hypothalamic Microglia.
Obesity
Visfatin, low-grade inflammation and body mass index (BMI).
Obesity
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Obesity
Visfatin--a review.
Obesity
Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.
Obesity
VISFATIN/PBEF and Atherosclerosis-Related Diseases.
Obesity
Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders.
Obesity
Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.
Obesity
Visfatin: the missing link between intra-abdominal obesity and diabetes?
Obesity
Weighted gene co-expression network analysis of expression data of monozygotic twins identifies specific modules and hub genes related to BMI.
Obesity
[Adipocytokines: potential biomarkers for childhood obesity and anorexia nervosa?]
Obesity
[Association between both resistin, visfatin and insulin resistance as well as ? cell function in the first-degree relatives of type 2 diabetes mellitus.]
Obesity
[Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female].
Obesity
[Effects of visfatin gene polymorphisms on glycolipid metabolism and exercise-induced weight reduction in obesity].
Obesity
[Inflammatory biomarkers: the link between obesity and associated pathologies]
Obesity
[Novel adipokines: links between obesity and atherosclerosis].
Obesity
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Obesity
[Research advances on the roles of nicotinamide phosphoribosyltransferase in inflammation].
Obesity
[Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases].
Obesity
[The research advances in the relationship between visfatin and cancer].
Obesity
[The role of visfatin in the pathophysiology of human]
Obesity, Abdominal
An evaluation of visfatin levels in obese subjects.
Obesity, Abdominal
Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?
Obesity, Abdominal
Effect of exercise training on plasma visfatin and eotaxin levels.
Obesity, Abdominal
Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
Obesity, Abdominal
Ethnic-specific Correlations of Visfatin With Circulating Markers of Endothelial Inflammation and Function.
Obesity, Abdominal
High-density lipoprotein inhibits ox-LDL-induced adipokine secretion by upregulating SR-BI expression and suppressing ER Stress pathway.
Obesity, Abdominal
Metabolic effects associated with adipose tissue distribution.
Obesity, Abdominal
The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity.
Obesity, Abdominal
The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women.
Obesity, Abdominal
The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Obesity, Abdominal
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Obesity, Abdominal
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Obesity, Abdominal
[Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy].
Obesity, Morbid
A Common Haplotype in NAPEPLD Is Associated With Severe Obesity in a Norwegian Population-Based Cohort (the HUNT Study).
Obesity, Morbid
A Rare Variant in the Visfatin Gene (NAMPT/PBEF1) Is Associated With Protection From Obesity.
Obesity, Morbid
Acute and Chronic Effects of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Visfatin and Apelin Levels in Patients with Severe Obesity.
Obesity, Morbid
C-peptide modifies leptin and visfatin secretion in human adipose tissue.
Obesity, Morbid
Plasma visfatin levels and gene expression in morbidly obese women with associated fatty liver disease.
Obstetric Labor, Premature
Evidence for differential regulation of the adipokine visfatin in the maternal and fetal compartments in normal spontaneous labor at term.
Obstetric Labor, Premature
Maternal plasma visfatin in preterm labor.
Obstetric Labor, Premature
The role of visfatin (PBEF/Nampt) in pregnancy complications.
Obstetric Labor, Premature
Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.
Osteoarthritis
Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee.
Osteoarthritis
An extensive review regarding the adipokines in the pathogenesis and progression of osteoarthritis.
Osteoarthritis
An Update on the Emerging Role of Visfatin in the Pathogenesis of Osteoarthritis and Pharmacological Intervention.
Osteoarthritis
Associations between Adipokines in Arthritic Disease and Implications for Obesity.
Osteoarthritis
Can adipokines serum levels be used as biomarkers of hand osteoarthritis?
Osteoarthritis
Circulating levels of adiponectin, resistin, and visfatin after mud-bath therapy in patients with bilateral knee osteoarthritis.
Osteoarthritis
Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis.
Osteoarthritis
Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis.
Osteoarthritis
Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis.
Osteoarthritis
Melatonin inhibits Sirt1-dependent NAMPT and NFAT5 signaling in chondrocytes to attenuate osteoarthritis.
Osteoarthritis
NAMPT (visfatin), a direct target of hypoxia-inducible factor-2?, is an essential catabolic regulator of osteoarthritis.
Osteoarthritis
Pro-inflammatory actions of visfatin/Nampt involve regulation of insulin signaling pathway and Nampt enzymatic activity.
Osteoarthritis
Reciprocal regulation by hypoxia-inducible factor-2? and the NAMPT-NAD(+)-SIRT axis in articular chondrocytes is involved in osteoarthritis.
Osteoarthritis
Strong association of the polymorphisms in PBEF1 and knee OA risk: a two-stage population-based study in China.
Osteoarthritis
The current progress in understanding the molecular functions and mechanisms of visfatin in osteoarthritis.
Osteoarthritis
The Effects of Adipokines on Cartilage and Meniscus Catabolism.
Osteoarthritis
Visfatin alters the cytokine and matrix-degrading enzyme profile during osteogenic and adipogenic MSC differentiation.
Osteoarthritis
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Osteoarthritis
Visfatin increases ICAM-1 expression and monocyte adhesion in human osteoarthritis synovial fibroblasts by reducing miR-320a expression.
Osteoarthritis
Visfatin Increases VEGF-dependent Angiogenesis of Endothelial Progenitor Cells during Osteoarthritis Progression.
Osteoarthritis
[The nicotinamide-phosphoribosiltransferase as a marker of systemic inflammation under osteoarthrosis.]
Osteoarthritis, Hip
eNAMPT Is Localised to Areas of Cartilage Damage in Patients with Hip Osteoarthritis and Promotes Cartilage Catabolism and Inflammation.
Osteoarthritis, Knee
Circulating levels of adiponectin, resistin, and visfatin after mud-bath therapy in patients with bilateral knee osteoarthritis.
Osteoarthritis, Knee
Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis.
Osteoarthritis, Knee
Synovial fluid adipokines are associated with clinical severity in knee osteoarthritis: a cross-sectional study in female patients with joint effusion.
Osteophyte
Expression of adipokines in osteoarthritis osteophytes and their effect on osteoblasts.
Osteophyte
Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis.
Osteophyte
Initial responses of articular tissues in a murine high-fat diet-induced osteoarthritis model: pivotal role of the IPFP as a cytokine fountain.
Osteoporosis
Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
Osteoporosis
Dietary fat intake associated with bone mineral density among visfatin genotype in obese people.
Osteoporosis
Epigenetic regulation of Runx2 transcription and osteoblast differentiation by nicotinamide phosphoribosyltransferase.
Osteoporosis
Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-?B ligand-induced osteoclast differentiation in vitro.
Osteoporosis
Research on the correlation of diabetes mellitus complicated with osteoporosis with lipid metabolism, adipokines and inflammatory factors and its regression analysis.
Osteoporosis
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
Osteoporosis
Visfatin alters the cytokine and matrix-degrading enzyme profile during osteogenic and adipogenic MSC differentiation.
Osteoporosis
Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis.
Osteoporosis, Postmenopausal
The influence of Visfatin, RBP-4 and insulin resistance on bone mineral density in women with treated primary osteoporosis.
Osteosarcoma
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
Osteosarcoma
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Osteosarcoma
Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
Osteosarcoma
Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.
Osteosarcoma
Visfatin promotes osteosarcoma cell migration and invasion via induction of epithelial-mesenchymal transition.
Osteosarcoma
Visfatin triggers the in vitro migration of osteosarcoma cells via activation of NF-?B/IL-6 signals.
Ovarian Neoplasms
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Ovarian Neoplasms
BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.
Ovarian Neoplasms
Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
Ovarian Neoplasms
Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma ME45 cells.
Ovarian Neoplasms
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
Ovarian Neoplasms
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Ovarian Neoplasms
Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers.
Ovarian Neoplasms
Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study.
Ovarian Neoplasms
Visfatin derived from ascites promotes ovarian cancer cell migration through Rho/ROCK signaling-mediated actin polymerization.
Overweight
Adenovirus36 infection expresses cellular APMI and Visfatin genes in overweight Uygur individuals.
Overweight
Adipose tissue-derived cytokines and their correlations with clinical characteristics in Vietnamese patients with type 2 diabetes mellitus.
Overweight
Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity.
Overweight
Comparing the prolonged effect of interval versus continuous aerobic exercise on blood inflammatory marker of Visfatin level and body mass index of sedentary overweigh/fat female college students.
Overweight
Effect of substituting saturated with monounsaturated fatty acids on serum visfatin levels and insulin resistance in overweight women: A randomized cross-over clinical trial.
Overweight
Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats.
Overweight
Effects of increased physical activity and/or weight loss diet on serum myokine and adipokine levels in overweight adults with impaired glucose metabolism.
Overweight
Elevated vaspin and leptin levels are associated with obesity in prepubertal Korean children.
Overweight
Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.
Overweight
in vivo Suppression of Visfatin by Oral Glucose Uptake: Evidence for a Novel Incretin-Like Effect by Glucagon-Like Peptide-1 (GLP-1).
Overweight
Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome.
Overweight
Plasma visfatin level in women with polycystic ovary syndrome.
Overweight
Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Overweight
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Overweight
Relationship of visfatin level to pancreatic endocrine hormone level, HOMA-IR index, and HOMA ?-cell index in overweight women who performed hydraulic resistance exercise.
Overweight
Resistance training increases muscle NAD+ and NADH concentrations as well as NAMPT protein levels and global sirtuin activity in middle-aged, overweight, untrained individuals.
Overweight
Role of Nampt and Visceral Adiposity in Esophagogastric Junction Adenocarcinoma.
Overweight
SERUM BILIRUBIN CORRELATES WITH SERUM ADIPOKINES IN NORMAL WEIGHT AND OVERWEIGHT ASYMPTOMATIC ADULTS.
Overweight
Serum visfatin concentration and its relationship with sex hormones in obese Saudi women.
Overweight
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Overweight
Study of visfatin expression in acne patients in tissue and serum.
Overweight
Visfatin as a predictor for growth of fetus and infant.
Overweight
Visfatin in juvenile obesity - the effect of obesity intervention and sex.
Overweight
Visfatin, low-grade inflammation and body mass index (BMI).
Overweight
Visfatin, resistin, hsCRP and insulin resistance in relation to abdominal obesity in women with rheumatoid arthritis.
Overweight
Visfatin, TNF-alpha and IL-6 mRNA Expression is Increased in Mononuclear Cells from Type 2 Diabetic Women.
Pancreatic Neoplasms
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.
Pancreatic Neoplasms
Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Pancreatic Neoplasms
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Pancreatic Neoplasms
Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
Pancreatic Neoplasms
Preclinical efficacy of the novel competitive NAMPT inhibitor STF-118804 in pancreatic cancer.
Pancreatic Neoplasms
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Pancreatitis
Admission Visfatin Levels Predict Pancreatic and Peripancreatic Necrosis in Acute Pancreatitis and Correlate With Clinical Severity.
Pancreatitis
Circulating levels of visfatin, resistin and pro-inflammatory cytokine interleukin-8 in acute pancreatitis.
Pancreatitis
Inhibition of nicotinamide phosphoribosyltransferase protects against acute pancreatitis via modulating macrophage polarization and its related metabolites.
Pancreatitis
Obesity and the risk of severe acute pancreatitis.
Pancreatitis, Alcoholic
Inhibition of nicotinamide phosphoribosyltransferase protects against acute pancreatitis via modulating macrophage polarization and its related metabolites.
Paralysis
Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death.
Paralysis
Metabolomic and transcriptional profiling reveals bioenergetic stress and activation of cell death and inflammatory pathways in vivo after neuronal deletion of NAMPT.
Parkinson Disease
Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease.
Pediatric Obesity
Adipocytokine levels in children: effects of fatness and training.
Pediatric Obesity
Adiponectin, Resistin, and Visfatin in Childhood Obesity and Exercise.
Pediatric Obesity
Common variants in LEPR, IL6, AMD1, and NAMPT do not associate with risk of juvenile and childhood obesity in Danes: a case-control study.
Pediatric Obesity
Plasma visfatin concentrations in childhood obesity: relationships with insulin resistance and anthropometric indices.
Pediatric Obesity
Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol.
Pediatric Obesity
The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
Pediatric Obesity
Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
Pediatric Obesity
Visfatin: the link between inflammation and childhood obesity.
Pediatric Obesity
[Relationship between serum visfatin level and children and adolescent obesity and non-alcoholic fatty liver disease].
Pemphigus
The effect of l-carnitine supplementation on serum levels of omentin-1, visfatin and SFRP5 and glycemic indices in patients with pemphigus vulgaris: A randomized, double-blind, placebo-controlled clinical trial.
Peri-Implantitis
Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study.
Pericarditis
Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: biomarkers of disease activity? A preliminary report.
Periodontal Diseases
Association of Serum and Crevicular Visfatin Levels in Periodontal Health and Disease With Type 2 Diabetes Mellitus.
Periodontal Diseases
Comparative Evaluation of Salivary Visfatin Levels in Healthy and Periodontally Diseased Patients before and after Scaling and Root Planing.
Periodontal Diseases
Correlation of serum adipocytokine levels with glycolipid metabolism and inflammatory factors in obese patients with periodontal disease.
Periodontal Diseases
Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease.
Periodontal Diseases
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Periodontal Diseases
Evaluation of association between Porphyromonas gingivalis and visfatin levels in chronic periodontitis patients.
Periodontal Diseases
Filifactor alocis and Tumor Necrosis Factor-Alpha Stimulate Synthesis of Visfatin by Human Macrophages.
Periodontal Diseases
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
Periodontal Diseases
Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome.
Periodontal Diseases
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Periodontal Diseases
Possible interaction between visfatin, periodontal infection, and other systemic diseases: A brief review of literature.
Periodontal Diseases
Salivary Visfatin Concentration in Response to Non-surgical Periodontal Therapy.
Periodontal Diseases
The Role of Visfatin (Adipocytokine) Biomarker in Oral Health and Diseases among Nonobese Indian Population: A Proteomic Assay.
Periodontal Diseases
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Periodontal Diseases
Visfatin levels in gingival crevicular fluid and serum before and after non-surgical treatment for periodontal diseases.
Periodontal Pocket
Porphyromonas gingivalis and Epstein-Barr Virus Are Associated With Increased Levels of Visfatin in Gingival Crevicular Fluid.
Periodontitis
Effect of non-surgical periodontal treatment on three salivary adipokines in diabetic patients with periodontitis.
Periodontitis
Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus.
Periodontitis
Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study.
Periodontitis
Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation.
Periodontitis
Filifactor alocis and Tumor Necrosis Factor-Alpha Stimulate Synthesis of Visfatin by Human Macrophages.
Periodontitis
Gingival Crevicular Fluid and Serum Visfatin Concentration: Their Relationship in Periodontal Health and Disease.
Periodontitis
Increased visfatin expression is associated with nuclear factor-kappa B and phosphatidylinositol 3-kinase in periodontal inflammation.
Periodontitis
Interlinking Periodontitis and Type 2 Diabetes Mellitus by Assessment of Crevicular Visfatin Levels in Health and in Disease Before and After Initial Periodontal Therapy.
Periodontitis
NAMPT enzyme activity regulates catabolic gene expression in gingival fibroblasts during periodontitis.
Periodontitis
Non-Surgical Periodontal Therapy Reduces Saliva Adipokines and Matrix Metalloproteinases Levels in Periodontitis.
Periodontitis
Periodontitis contributes to aberrant metabolism in type 2 diabetes mellitus rats by stimulating the expression of adipokines.
Periodontitis
Porphyromonas gingivalis and Epstein-Barr Virus Are Associated With Increased Levels of Visfatin in Gingival Crevicular Fluid.
Periodontitis
Regulation of NAMPT in Human Gingival Fibroblasts and Biopsies.
Periodontitis
Regulation of regenerative periodontal healing by NAMPT.
Periodontitis
Regulation of visfatin by microbial and biomechanical signals in PDL cells.
Periodontitis
Salivary Visfatin Concentration in Chronic Periodontitis Patients.
Periodontitis
Salivary Visfatin Concentration in Response to Non-surgical Periodontal Therapy.
Periodontitis
Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells.
Periodontitis
The role of adipokines in periodontal infection and healing.
Periodontitis
The Role of Visfatin (Adipocytokine) Biomarker in Oral Health and Diseases among Nonobese Indian Population: A Proteomic Assay.
Periodontitis
The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease.
Periodontitis
Visfatin expression in gingival tissues of chronic periodontitis and aggressive periodontitis patients: An immunohistochemical analysis.
Periodontitis
Visfatin regulates Pg LPS-induced proinflammatory/prodegradative effects in healthy and inflammatory periodontal cells partially via NF-?B pathway.
Peripheral Nervous System Diseases
Dysregulation of NAD+ Metabolism Induces a Schwann Cell Dedifferentiation Program.
Peripheral Nervous System Diseases
Pharmacological augmentation of nicotinamide phosphoribosyltransferase (NAMPT) protects against paclitaxel-induced peripheral neuropathy.
Pheochromocytoma
Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway.
Pneumonia
Elevated plasma visfatin concentrations in patients with community-acquired pneumonia.
Pneumonia
The Association of Chlamydia pneumonia and Helicobacter pylori IgG Seropositivity With Omentin-1, Visfatin and Adiponectin Levels in Postmenopausal Women.
Pneumonia
Up-regulation of SFTPB expression and attenuation of acute lung injury by pulmonary epithelial cell-specific NAMPT knockdown.
Pneumonia
Visfatin Exerts Immunotherapeutic Effects in Lipopolysaccharide-Induced Acute Lung Injury in Murine Model.
Pneumonia
Visfatin levels in patients with severe pneumonia.
Polycystic Ovary Syndrome
Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation.
Polycystic Ovary Syndrome
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Effect of Omega-3 Supplementation on Visfatin, Adiponectin, and Anthropometric Indices in Women with Polycystic Ovarian Syndrome.
Polycystic Ovary Syndrome
Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Evidence for serum visfatin but not adiponectin or resistin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome.
Polycystic Ovary Syndrome
Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome.
Polycystic Ovary Syndrome
High level of visfatin and the activation of Akt and ERK1/2 signaling pathways are associated with endometrium malignant transformation in polycystic ovary syndrome.
Polycystic Ovary Syndrome
High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis.
Polycystic Ovary Syndrome
Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis.
Polycystic Ovary Syndrome
Increased plasma visfatin concentrations in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin.
Polycystic Ovary Syndrome
Is there association between vitamin D levels, apelin 36, and visfatin in PCOS?
Polycystic Ovary Syndrome
Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels.
Polycystic Ovary Syndrome
Omega-3 Fatty Acids Improve Glucose Metabolism without Effects on Obesity Values and Serum Visfatin Levels in Women with Polycystic Ovary Syndrome.
Polycystic Ovary Syndrome
Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance.
Polycystic Ovary Syndrome
Plasma visfatin level in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Plasma visfatin levels and mRNA expression of visfatin in peripheral blood mononuclear cells and peripheral blood monocyte-derived macrophages from normal weight females with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Plasma Visfatin Levels in Adolescents with Polycystic Ovary Syndrome: A Prospective Case-Control Study.
Polycystic Ovary Syndrome
Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum visfatin and adiponectin - markers in women with polycystic ovarian syndrome.
Polycystic Ovary Syndrome
Serum visfatin in Asian women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum visfatin is differentially regulated by insulin and free Fatty acids in healthy men.
Polycystic Ovary Syndrome
Serum visfatin is elevated in Chinese women with polycystic ovary syndrome, but might not be a reliable predictor of their glucose intolerance.
Polycystic Ovary Syndrome
Serum visfatin levels in non-obese women with polycystic ovary syndrome and matched controls.
Polycystic Ovary Syndrome
Serum visfatin levels in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Spleen-yang-deficiency patients with polycystic ovary syndrome have higher levels of visfatin.
Polycystic Ovary Syndrome
Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation.
Polycystic Ovary Syndrome
Visfatin and resistin serum levels in normal-weight and obese women with polycystic ovary syndrome.
Polycystic Ovary Syndrome
Visfatin and SREBP-1c mRNA Expressions and Serum Levels Among Egyptian Women with Polycystic Ovary Syndrome.
Polycystic Ovary Syndrome
[Clinical significance and changes of serum visfatin, adiponectin and leptin levels in patients with polycystic ovarian syndrome]
Polycystic Ovary Syndrome
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
Polycystic Ovary Syndrome
[The research advances in the relationship between visfatin and cancer].
Polycythemia Vera
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Pre-Eclampsia
Adipokine Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy.
Pre-Eclampsia
Association between circulating visfatin and pre-eclampsia: a systematic review and meta-analysis.
Pre-Eclampsia
Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA?
Pre-Eclampsia
Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia.
Pre-Eclampsia
Effect of intrauterine growth pattern on serum visfatin concentrations in full-term infants at birth and at 6 months of life.
Pre-Eclampsia
Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Pre-Eclampsia
Increased visfatin and leptin in pregnancies complicated by pre-eclampsia.
Pre-Eclampsia
Maternal adiponectin and visfatin concentrations in normal and complicated pregnancies.
Pre-Eclampsia
Maternal and neonatal circulating visfatin concentrations in patients with pre-eclampsia and a small-for-gestational age neonate.
Pre-Eclampsia
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
Pre-Eclampsia
NAMPT levels are inversely related to nitric oxide formation and positively related to soluble fms-like tyrosine kinase-1 levels in preeclampsia.
Pre-Eclampsia
NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia.
Pre-Eclampsia
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Pre-Eclampsia
Serum adipocytokines and adiposity as predictive indices of preeclampsia.
Pre-Eclampsia
Serum levels of the adipokine visfatin are increased in pre-eclampsia.
Pre-Eclampsia
Serum visfatin levels in late pregnancy and pre-eclampsia.
Pre-Eclampsia
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
Pre-Eclampsia
The role of visfatin (PBEF/Nampt) in pregnancy complications.
Pre-Eclampsia
Visfatin serum levels are increased in women with preeclampsia: A case-control study.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Adipokines in young survivors of childhood acute lymphocytic leukemia revisited: beyond fat mass.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia.
Prediabetic State
Anthocyanins regulate serum adipsin and visfatin in patients with prediabetes or newly diagnosed diabetes: a randomized controlled trial.
Prediabetic State
Plasma adiponectin, visfatin, leptin, and resistin levels and the onset of colonic polyps in patients with prediabetes.
Prediabetic State
Visfatin concentrations in obese patients in relation to the presence of newly diagnosed glucose metabolism disorders.
Pregnancy Complications
Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function.
Pregnancy Complications
The role of visfatin (PBEF/Nampt) in pregnancy complications.
Premature Birth
Relationship between vitamin D and gestational diabetes in overweight or obese pregnant women may be mediated by adiponectin.
Premature Birth
Umbilical cord blood and maternal visfatin (PBEF/NAMPT) concentrations in preterm birth with and without preterm premature rupture of membranes.
Primary Myelofibrosis
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Prostatic Neoplasms
A Novel Role for the Adipokine Visfatin/Pre-B Cell Colony-enhancing Factor 1 in Prostate Carcinogenesis.
Prostatic Neoplasms
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.
Prostatic Neoplasms
NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.
Prostatic Neoplasms
Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells.
Prostatic Neoplasms
Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: Novel biomarker and therapeutic target.
Proteinuria
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
Proteinuria
Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.
Psoriasis
Assessment of visfatin concentrations in the serum of male psoriatic patients in relation to metabolic abnormalities.
Psoriasis
Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis.
Psoriasis
Association of Adipokines, Insulin Resistance, Hypertension and Dyslipidemia in Patients with Psoriasis Vulgaris.
Psoriasis
Circulating levels of Apelin 36 in patients with mild to moderate psoriasis.
Psoriasis
Correlation of metabolic syndrome with serum omentin-1 and visfatin levels and disease severity in psoriasis and psoriatic arthritis.
Psoriasis
Gene expression profiling of peripheral blood mononuclear cells in endometriosis identifies genes altered in non-gynaecologic chronic inflammatory diseases.
Psoriasis
Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis?
Psoriasis
Mild to moderate psoriasis is associated with oxidative stress, subclinical atherosclerosis, and endothelial dysfunction.
Psoriasis
Obesity in autoimmune diseases: not a passive bystander.
Psoriasis
Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset "sine psoriasis".
Psoriasis
Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers.
Psoriasis
Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab.
Psoriasis
Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-? inhibitors: results of a retrospective analysis.
Psoriasis
Serum levels of visfatin and omentin-1 in patients with psoriasis and their relation to disease severity.
Psoriasis
Serum Visfatin, Adiponectin, and Tumor Necrosis Factor Alpha (TNF-?) Levels in Patients with Psoriasis and their Correlation with Disease Severity.
Psoriasis
Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.
Psoriasis
Visfatin Enhances CXCL8, CXCL10, and CCL20 Production in Human Keratinocytes.
Psoriasis
Visfatin Enhances the Production of Cathelicidin Antimicrobial Peptide, Human ?-Defensin-2, Human ?-Defensin-3, and S100A7 in Human Keratinocytes and Their Orthologs in Murine Imiquimod-Induced Psoriatic Skin.
Pulmonary Arterial Hypertension
Direct eNAMPT Involvement in Pulmonary Hypertension and Vascular Remodeling: Transcriptional Regulation by SOX and HIF2?.
Pulmonary Arterial Hypertension
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase.
Pulmonary Arterial Hypertension
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension.
Pulmonary Disease, Chronic Obstructive
Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Circulating visfatin in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Evaluation of Serum Resistin, Visfatin, and Chemerin Levels in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis.
Pulmonary Disease, Chronic Obstructive
Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Serum levels of visfatin, sirtuin-1, and interleukin-6 in stable and acute exacerbation of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
The role of adipokines in the pathogenesis and course of selected respiratory diseases.
Pulmonary Disease, Chronic Obstructive
Visfatin levels in patients with severe pneumonia.
Purpura
Elevated serum levels of visfatin in patients with henoch-schönlein purpura.
Pyelonephritis
Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis.
Pyelonephritis
The Role of Nicotinamide Phosphoribosyltransferase in Pregnancy: A Review.
Radiation Pneumonitis
Involvement of eNAMPT/TLR4 signaling in murine radiation pneumonitis: protection by eNAMPT neutralization.
Renal Insufficiency
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
Renal Insufficiency
Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Renal Insufficiency
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Renal Insufficiency, Chronic
Association between elevated visfatin and carotid atherosclerosis in patients with chronic kidney disease.
Renal Insufficiency, Chronic
Association between visfatin levels and coronary artery disease in patients with chronic kidney disease.
Renal Insufficiency, Chronic
Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes.
Renal Insufficiency, Chronic
Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells.
Renal Insufficiency, Chronic
Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study.
Renal Insufficiency, Chronic
Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
Renal Insufficiency, Chronic
Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure.
Renal Insufficiency, Chronic
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels.
Renal Insufficiency, Chronic
Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease.
Renal Insufficiency, Chronic
Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients.
Reperfusion Injury
Adiponectin and resistin protect steatotic livers undergoing transplantation.
Reperfusion Injury
The function of nicotinamide phosphoribosyltransferase in the heart.
Reperfusion Injury
Visfatin reduces hippocampal CA1 cells death and improves learning and memory deficits after transient global ischemia/reperfusion.
Reperfusion Injury
Visfatin relieves myocardial ischemia-reperfusion injury through activation of PI3K/Akt/HSP70 signaling axis.
Respiratory Distress Syndrome
Clinical role of serum pre-B cell colony-enhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome.
Respiratory Distress Syndrome
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Respiratory Distress Syndrome
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Respiratory Distress Syndrome
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.
Respiratory Distress Syndrome
Novel Mechanism for Nicotinamide Phosphoribosyltransferase Inhibition of TNF-?-Mediated Apoptosis in Human Lung Endothelial Cells.
Respiratory Distress Syndrome
Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome.
Respiratory Distress Syndrome
[The influence of pre-B-cell colony enhancing factor on adhesive molecule in pulmonary cells in rats with acute lung injury/acute respiratory distress syndrome].
Retinal Diseases
Loss of NAMPT in aging retinal pigment epithelium reduces NAD+ availability and promotes cellular senescence.
Retinal Neovascularization
Visfatin promotes angiogenesis of RF/6A cells through upregulation of VEGF/VEGFR-2 under high-glucose conditions.
Retinopathy of Prematurity
IGF-I and Visfatin Levels in Retinopathy of Prematurity.
Rhabdomyosarcoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Rhabdomyosarcoma, Alveolar
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Rheumatic Diseases
Adipokines as emerging mediators of immune response and inflammation.
Rheumatic Diseases
Adipokines in connective tissue diseases.
Rheumatic Diseases
Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis.
Rheumatic Diseases
The association between clinically suspect arthralgia and adipokines in obese patients.
Rheumatic Diseases
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Rheumatic Diseases
What's new in our understanding of the role of adipokines in rheumatic diseases?
Rheumatic Diseases
[Adipocytokines: emerging mediators of the immune response and inflammation].
Rosacea
Sebocytes differentially express and secrete adipokines.
Sarcoidosis
Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?
Sarcoma
Increased Nicotinamide Phosphoribosyltransferase in Rhabdomyosarcomas and Leiomyosarcomas Compared to Skeletal and Smooth Muscle Tissue.
Sarcoma
Nicotinamide Phosphoribosyl Transferase Is Increased in Osteosarcomas and Chondrosarcomas Compared to Benign Bone and Cartilage.
Sarcoma, Ewing
EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Sarcoma, Ewing
EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Sarcoma, Ewing
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma.
Sarcoma, Ewing
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma.
Scleroderma, Diffuse
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
Scleroderma, Systemic
A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
Scleroderma, Systemic
Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis.
Scleroderma, Systemic
The role of adipokines in systemic sclerosis: a missing link?
Scleroderma, Systemic
Visfatin and chemerin levels correspond with inflammation and might reflect the bridge between metabolism, inflammation and fibrosis in patients with systemic sclerosis.
Scleroderma, Systemic
Visfatin levels and intima-media thicknesses in rheumatic diseases.
Seizures
Acute Phase Serum Leptin, Adiponectin, Interleukin-6, and Visfatin Are Altered in Chinese Children With Febrile Seizures: A Cross-Sectional Study.
Seizures, Febrile
Acute Phase Serum Leptin, Adiponectin, Interleukin-6, and Visfatin Are Altered in Chinese Children With Febrile Seizures: A Cross-Sectional Study.
Sepsis
Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study.
Sepsis
Clinical role of serum pre-B cell colony-enhancing factor in ventilated patients with sepsis and acute respiratory distress syndrome.
Sepsis
Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis.
Sepsis
Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury.
Sepsis
Essential Role of Visfatin in Lipopolysaccharide and Colon Ascendens Stent Peritonitis-Induced Acute Lung Injury.
Sepsis
Extracellular nicotinate phosphoribosyltransferase binds Toll like receptor 4 and mediates inflammation.
Sepsis
Maternal plasma concentration of the pro-inflammatory adipokine pre-B-cell-enhancing factor (PBEF)/visfatin is elevated in pregnant patients with acute pyelonephritis.
Sepsis
Metabolic and molecular insights into an essential role of nicotinamide phosphoribosyltransferase.
Sepsis
microRNA-300/NAMPT regulates inflammatory responses through activation of AMPK/mTOR signaling pathway in neonatal sepsis.
Sepsis
MiR-96-5p alleviates inflammatory responses by targeting NAMPT and regulating the NF-?B pathway in neonatal sepsis.
Sepsis
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
Sepsis
NAMPT serum levels are selectively elevated in acute infectious disease and in acute relapse of chronic inflammatory diseases in children.
Sepsis
Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.
Sepsis
Pre-B-cell colony-enhancing factor and its clinical correlates with acute lung injury and sepsis.
Sepsis
The Role of Adipose Tissue and Adipokines in Sepsis: Inflammatory and Metabolic Considerations, and the Obesity Paradox.
Sepsis
Visfatin induces sickness responses in the brain.
Sepsis
Visfatin Serum Levels Predict Mortality in Critically Ill Patients.
Sepsis
Visfatin/pre-B-cell colony-enhancing factor: a protein with various suggested functions.
Shock, Septic
Circulating eNampt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study.
Shock, Septic
NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation.
Short Bowel Syndrome
Ghrelin, visfatin and irisin in children with short bowel syndrome.
Sialadenitis
Dual Roles of Nicotinamide Phosphoribosyltransferase as a Promising Target for Cancer Radiotherapy.
Sleep Apnea Syndromes
Obesity and obstructive sleep apnea syndrome.
Sleep Apnea, Obstructive
Adiponectin, Omentin, Ghrelin, and Visfatin Levels in Obese Patients with Severe Obstructive Sleep Apnea.
Sleep Apnea, Obstructive
Coexistence of obstructive sleep apnea and telomerase activity, concentration of selected adipose tissue hormones and vascular endothelial function in patients with arterial hypertension.
Sleep Apnea, Obstructive
Dietary and physical activity patterns in children with obstructive sleep apnea.
Sleep Apnea, Obstructive
Visfatin as a predictor of obstructive sleep apnea in atrial fibrillation patients.
Sleep Deprivation
Sleep Deficiency is a Modifiable Risk Factor for Obesity and Cognitive Impairment and Associated with Elevated Visfatin.
Small Cell Lung Carcinoma
Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
Spinal Cord Injuries
The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.
Spondylitis, Ankylosing
Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-? antagonist therapy.
Spondylitis, Ankylosing
Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression.
Spondylitis, Ankylosing
The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis
Squamous Cell Carcinoma of Head and Neck
Elevated plasma level of visfatin/pre-b cell colony-enhancing factor in male oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
ST Elevation Myocardial Infarction
Interpretation of elevated plasma visfatin concentrations in patients with ST-elevation myocardial infarction.
Starvation
Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans.
Starvation
Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling.
Stomach Neoplasms
Adipocyte Derived Hormones Gene Expression, Resistin and Visfatin, in AGS Gastric Cancer Cell Line.
Stomach Neoplasms
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer.
Stomach Neoplasms
Diet-induced obesity promotes murine gastric cancer growth through a nampt/sirt1/c-myc positive feedback loop.
Stomach Neoplasms
Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients.
Stomach Neoplasms
High glucose promotes gastric cancer chemoresistance in vivo and in vitro.
Stomach Neoplasms
Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil.
Stomach Neoplasms
Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.
Stomach Neoplasms
Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
Stomach Neoplasms
Synergistic Effects of Resistin and Visfatin as Adipocyte Derived Hormones on Telomerase Gene Expression in AGS Gastric Cancer Cell Line.
Stomach Neoplasms
Visfatin effects on telomerase gene expression in AGS gastric cancer cell line.
Stomach Neoplasms
Visfatin facilitates gastric cancer malignancy by targeting snai1 via the NF-?B signaling.
Stroke
Association of serum vaspin, apelin, and visfatin levels and stroke risk in a Chinese case-control study.
Stroke
Cerebrovascular Disease: Consequences of Obesity-Induced Endothelial Dysfunction.
Stroke
Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke.
Stroke
High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome.
Stroke
Intracerebroventricular Delivery of Recombinant NAMPT Deters Inflammation and Protects Against Cerebral Ischemia.
Stroke
NAMPT as a Therapeutic Target against Stroke.
Stroke
Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway.
Stroke
Prognostic significance of plasma visfatin levels in patients with ischemic stroke.
Stroke
Selected adipose tissue hormones in the blood of patients with ischaemic cerebral stroke.
Stroke
Targeting NAMPT as a therapeutic strategy against stroke.
Stroke
The emerging role of leptin, Adiponectin and Visfatin in Ischemic/Hemorrhagic stroke.
Stroke
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
Stroke
Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis.
Subarachnoid Hemorrhage
Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage.
Temporomandibular Joint Disorders
Analysis of synovial fluid visfatin level in temporomandibular joint disorders.
Thrombocythemia, Essential
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Thrombocytopenia
Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
Thyroid Cancer, Papillary
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Thyroid Diseases
Sirtuin 1, Visfatin and IL-27 Serum Levels of Type 1 Diabetic Females in Relation to Cardiovascular Parameters and Autoimmune Thyroid Disease.
Thyroid Neoplasms
Changes of Nicotinamide Phosphoribosyltransferase Expressions in Thyroid Glands of Patients with Different Thyroid Pathologies.
Thyroid Neoplasms
Cystathione ?-Synthase Is Increased in Thyroid Malignancies.
Thyroid Neoplasms
Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas.
Thyroid Neoplasms
Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression.
Thyroiditis
Role of Nampt overexpression in a rat model of Hashimoto's thyroiditis and its mechanism of action.
Thyroiditis, Autoimmune
Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.
Thyroiditis, Autoimmune
Visfatin level in children and adolescents with autoimmune thyroiditis.
Triple Negative Breast Neoplasms
Correction: Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Dezocine, An Opioid Analgesic, Exerts Antitumor Effects in Triple-Negative Breast Cancer by Targeting Nicotinamide Phosphoribosyltransferase.
Triple Negative Breast Neoplasms
Epigenetic Regulation of NAMPT by NAMPT-AS Drives Metastatic Progression in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Optical Redox Imaging of Treatment Responses to Nampt Inhibition and Combination Therapy in Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Tuberculosis, Pulmonary
The mRNA expression of visfatin and lipocalin-2 in peripheral blood mononuclear cells from patients with pulmonary tuberculosis.
Uremia
Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels.
Urinary Bladder Neoplasms
Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.
Urinary Bladder Neoplasms
Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer.
Vascular Diseases
Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment.
Vascular Diseases
Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells.
Vascular Diseases
Visfatin, glucose metabolism and vascular disease: a review of evidence.
Ventilator-Induced Lung Injury
Endotoxin- and mechanical stress-induced epigenetic changes in the regulation of the nicotinamide phosphoribosyltransferase promoter.
Ventilator-Induced Lung Injury
Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury.
Ventilator-Induced Lung Injury
MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866.
Ventilator-Induced Lung Injury
Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration.
Ventilator-Induced Lung Injury
Nicotinamide phosphoribosyltransferase inhibitor is a novel therapeutic candidate in murine models of inflammatory lung injury.
Virus Diseases
Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection.
Virus Diseases
Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT.
Waldenstrom Macroglobulinemia
DUAL NAMPT AND BTK TARGETING LEADS TO SYNERGISTIC KILLING OF WALDENSTROM`S MACROGLOBULINEMIA CELLS REGARDLESS OF MYD88 AND CXCR4 SOMATIC MUTATIONS STATUS.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2.4.2.12 nicotinamide phosphoribosyltransferase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
